

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Trajectories of disposable income before and after being diagnosed with multiple sclerosis: A nationwide registerbased cohort study in Sweden with a population-based reference group

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-020392
Article Type:	Research
Date Submitted by the Author:	03-Nov-2017
Complete List of Authors:	Murley, Chantelle; Karolinska Institutet Department of Clinical Neuroscience, Division of Insurance Medicine; Karolinska Institutet, Department of Learning, Informatics, Management and Ethics Mogard, Olof; Karolinska Insitutet, Department of Learning, Informatics, Management and Ethics Wiberg, Michael; Karolinska Institutet Department of Clinical Neuroscience, Division of Insurance Medicine Alexanderson, Kristina; Karolinska Institutet Department of Clinical Neuroscience, Division of Insurance Medicine Karampampa, Korinna; Karolinska Insitutet, Department of Learning, Informatics, Management and Ethics Friberg, Emilie; Karolinska Institutet Department of Clinical Neuroscience, Division of Insurance Medicine Tinghög, Petter; Karolinska Institutet Department of Clinical Neuroscience, Division of Insurance Medicine
Keywords:	Multiple sclerosis < NEUROLOGY, Welfare state, Economic impact, Sick leave, Insurance benefits, Income
	*



BMJ Open

1	Title: Trajectories of disposable income before and after being diagnosed with multiple sclerosis: A
2	nationwide register-based cohort study in Sweden with a population-based reference group
3	Authors and affiliations:
4 5	Chantelle Murley ^{1, 2} , Olof Mogard ² , Michael Wiberg ¹ , Kristina Alexanderson ¹ , Korinna Karampampa ² , Emilie Friberg ¹ , Petter Tinghög ^{1, 3}
6 7	¹ Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, SE- 171 77 Stockholm, Sweden.
8 9	² Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
10	³ Red Cross University College, SE-114 28 Stockholm, Sweden.
11	Corresponding author: Chantelle Murley
12 13	Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
14	Phone: +46 76 0603003
15	Fax: +46 (0)8 524 832 05
16	chantelle.murley@ki.se,
17	Abstract word count: 300 Text word count: 3910 Number of references: 44
18	Text word count: 3910
19	Number of references: 44
20	Number of tables: 4
21	Number of figures: 2
22	KEYWORDS: Multiple Sclerosis, Welfare state, Sick leave, Insurance benefits, Socioeconomic
23	status, Income
24	
21	
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

25 ABSTRACT:26 Objectives: Dis

Objectives: Disposable income (DI) encompasses multiple income sources and is a pertinent indicator
 of an individual's economic welfare, particularly in welfare states. We described how DI and three
 main components developed among people with multiple sclerosis (MS) in Sweden before and after
 diagnoses, and analysed whether their DI trajectory differed to a reference group.

30 Design: Population-based cohort study, with follow-up of annual sums of incomes from seven years

31 before to four years after diagnosis.

32 Setting: Swedish general population with data linked from two nationwide registers.

Participants: All residents diagnosed with MS in 2009, aged 25-59 (n=785) and a reference group
without MS randomly selected with stratified matching by four sociodemographic variables (n=7847):
sex; age; education level; and country of birth.

36 Primary and secondary outcome measures: The primary outcome measure, DI was defined as the 37 annual sum of total net incomes (earnings and benefits) minus taxes. Three main components of DI 38 were also separately analysed as annual sums: earnings; sickness absence benefits; and disability 39 pension benefits.

40 Results: We found no differences in mean annual DI between the people with and without MS by 41 independent t-tests at each follow-up year. Significant differences were found for the annual levels of 42 components of DI from diagnosis year by independent t-tests. A generalised estimating equation 43 evaluated the differences in the DI trajectory development between people with and without MS with 44 the result that the trajectory of MS patients developed in parallel to the references'. No association 45 with MS and economic welfare, as measured by DI, was found.

46 Conclusions: The key finding that the DI trajectory was unchanged around the years of MS diagnosis
47 despite differences in components highlights the disease's distinct financial burdens. The Swedish
48 welfare system was responsive to the decreased earnings through balancing DI by the morbidity49 related benefits around time of MS diagnosis.

2	50	ARTICLE SUMMARY:
4 5	51	Strengths and limitations
6 7	52	• The main strengths of this study include both the population-based design and use of nationwide
8 9	53	registers with high completeness and validity, which enabled measurement of multiple sources of
10 11	54	income including disposable income.
12 13	55	• The longitudinal study design with repeated measures of disposable income enabled the study of
14 15	56	the development of DI over 12 years, in addition to the difference in levels.
16 17	57	• While residual confounding cannot be excluded, the reference group was a randomised stratified
18 19	58	matched group from the general population at a ratio of 1:10.
20 21	59	• This study does not address the long-term association between economic welfare and MS as the
22 23	60	follow-up was only four years in the post diagnosis period.
24 25		
26 27	61	
28 29		
29 30		
31		
32		
33 34		
35		
36		
37		
38		
39		
40		
41		
42 43		
45 44		
44		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58 59		

60

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

1. INTRODUCTION

The chronic and progressive disease multiple sclerosis (MS) is the leading cause of non-traumatic neurological disability in younger adults.[1-5] People with MS (PwMS) in Sweden have a mean onset age of 32, but experience a time-lag before receiving a formal diagnosis.[6] Previous research has found MS to be associated with progressive work incapacity.[7-13] The indirect costs of PwMS of working age become a dominating cost as the disease progresses from a societal perspective, however, the impact of MS on the individual's economic welfare is relatively unknown.[6 14-16]

The wider socioeconomic context can mediate the economic impact of MS on the individual.[17 18] Sweden has a largely tax-financed universal healthcare system and welfare benefits to compensate a proportion of lost earnings due to morbidity-related work incapacity. The most substantial of these protections for PwMS are the temporary sickness absence (SA) and permanent disability pension (DP) benefits; both designed to compensate previous earnings reduced by morbidity-related absence. A higher proportion of PwMS receive the morbidity-related benefits, SA and DP, in comparison to the general population.[3 19] Studies show trends of PwMS experiencing differences in sources of income within a few years of symptom onset, indicating that morbidity-related benefits are an important source of income for PwMS to consider when investigating their economic situation.[20-23] Thus, earnings alone provides an incomplete picture of an individual's economic welfare; only that of the individual's labour market participation and income generation.[3 20] However, it is unclear what the collective impact of these changes in income sources are on the individual's economic welfare as earnings remain an important income source.[3] Thorough investigation on how MS affects the economic resources available to PwMS in Sweden necessitates the need to assess multiple sources of income in totality, and longitudinally, as effects between health status and economic welfare are not always manifested immediately.[3 19 24-29]

Disposable income (DI) is comprised of multiple income sources, allowing for a comprehensive description of economic welfare.[3 30] DI is the "sum of factor income (income from work and capital) and net income from transfers (government benefits), income taxes, and fees paid to the

BMJ Open

government".[20] An individual's consumption potential is better reflected with DI, than the individual income sources.[30] DI is more nuanced than earnings or dichotomous employment status, and can reflect the complexity of contemporary labour markets, employment patterns and multiple income sources.[31] With 62% of PwMS in Sweden receiving partial or full DP in 2005, compared to 14% of a matched reference group, there is a need for a composite income indicator to consider PwMS' financial welfare. [26] Despite an increasing number of studies on PwMS receiving SA and DP benefits or about earnings, little is known about how MS impacts one's DI trajectory development in a welfare state.[3 19 32] Recent longitudinal Danish studies applied DI concepts by combining both earnings and DP benefits, but not income from SA benefits, to suggest similar trajectories, while remaining in employment.[22 33] The full magnitude of the economic consequences for individuals with MS remains unknown in the welfare state.[3 32]

This study aimed to describe the development of disposable income (DI) and three main components (SA, DP, and earnings), among people diagnosed with MS in the years before and after diagnosis and compare with people without MS, in order to gain knowledge on the economic welfare of people Jez oni diagnosed with MS in a welfare state.

2. METHODS

2.1 Study design

We conducted a cohort study to measure the levels and development of mean annual DI and its main components (SA, DP, and earnings) among PwMS in relation to matched references without MS from the Swedish population. The index year of diagnosis, 2009, was defined as time point T₀, and the seven years of observation before and four years after diagnosis as T₋₇ to T₋₁ and T₊₁ to T₊₄, respectively.

2.2 Data sources

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

Person-level data, linked by the unique personal identity numbers assigned to every resident inSweden, were obtained from the following two nationwide Swedish registers:

BMJ Open

Statistics Sweden: Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA), to obtain sociodemographic variables and the sums of annual income from the different sources across follow-up.

117 2) National Board of Health and Welfare: *National Patient Registers*, to identify all people
118 with an MS diagnosis, from inpatient hospital treatment by the International Classification
119 (ICD) codes, ICD-9 (340) and 10 (G35) (1987-2009), and specialised outpatient treatment by
120 ICD-10 (2001-2009).

121 2.3 Study population

The study population was sourced from the total population registered as living in Sweden on 31 December 2009 (from LISA). The cohort of PwMS included all 785 PwMS with an incident MS diagnosis in 2009 and aged 25-59 years (that is, of working ages in all studied years, 65 years being the customary age for old-age pension in Sweden). All people with their first MS diagnosis according to the national patient registers in 2009 were included, excluding all with a previous MS diagnosis (according to both the in- and specialised out-patient registers).[26]

We established a matched reference cohort of people who before 2010, according to the in- and specialised out-patient registers, were not diagnosed with MS. Among all without MS, who according to LISA, lived in Sweden 31 December 2009, we randomly selected ten references for each PwMS, matched on age, gender, educational level, and birth country in 2009 (T_0). This produced a stratified matched reference group, which was similar to the MS cohort with relation to the distribution of the selected sociodemographic variables at the point of diagnosis. The 1:10 ratio of references could not be met for one individual with MS, with only seven possible references in the general Swedish population matching the particular combination of sociodemographic variables. In all, 7847 references were included at T_0 .

BMJ Open

The maximum number of years of observation was 12, with 97.3% (n= 764) of the PwMS and 97.8% (n=7671) of the reference group in the study at the end of follow-up (T_{+4}). Missing income data in LISA, which could be due to migration before/after the index year or death after T_0 , led to small proportions of individuals across both groups not being followed for the entirety of follow-up.

141 2.4 Variables

Our main outcome measure was annual **disposable income** (DI). We used the DI measure constructed by Statistics Sweden, contained in LISA. This was the sum of incomes after tax, with sources including: income from work and public benefits such as disability pension; sickness absence; disability allowance; unemployment compensation; old-age pension; and social assistance.[34] DI was an individualised measure of household DI, calculated as the sum of household incomes, adjusted for household size and the individual's consumption weight to produce a continuous variable.[34]

148 The three main components of DI for working-aged PwMS were also included as alternative economic149 outcome variables in analyses as the mean annual sum:

- Sickness absence (SA): All people living in Sweden above the age of 16 are covered by
 public sick-leave insurance if they receive income from work or unemployment benefits and,
 if due to disease or injury, have work incapacity. The Social Insurance Agency pays the
 granted sickness absence benefits, of up to 80% of lost earnings, at 100, 75, 50 or 25% of
 ordinary working hours. Among employees, the employer provides sick pay the first 13 days
 of a sick-leave spell after the first uncompensated day;
 - Disability pension (DP): All residents aged 19-64 can be granted disability pension if disease
 or injury leads to long-term or permanent work incapacity. Benefits of up to 64% of the lost
 earnings are paid by the Social Insurance Agency, at 100, 75, 50 or 25% of ordinary working
 hours; and
 - Earnings: Income from work was in the form of gross earnings. This included the sick pay
 provided by the employer during the first 14 days of a sick-leave spell.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

BMJ Open

All monetary values were presented in Swedish Krona (SEK) and adjusted for inflation by the Statistics Sweden Harmonised Consumer Price Index (HCPI) by the annual average 2016 value.[35] The following combination of sociodemographic variables sourced from LISA were included in the analyses as explanatory variables: Age (continuous, time variant): In addition, age was also computed into a new continuous variable to control for curvilinearity in the statistical analyses by squaring the values for age; Gender (binary); Educational level (categorical, time variant: elementary; high school; college or university; and missing); and Birth country (categorical: Sweden; Other Nordic Countries; Other EU25 Countries; Rest of World; and missing). The study cohort had near complete data with less than 0.25% missing values for country of birth, and 0.5% for educational level. 2.5 Ethical approval The project was approved by the Regional Ethical Review Board of Stockholm, Sweden. 2.6 Statistical analyses Data management and statistical analyses were conducted in SAS v.9.4, with the exception of generalised estimating equation (GEE) models, which were calculated in SPSS v.24. In our data management, we set 337 negative DI values between 2004 and 2013 to zero to prevent distortion of the DI means over time. This was required as Statistics Sweden changed how they coded DI in LISA; earlier years of follow-up had a lower limit of zero but from 2004, there was possibility of negative values. We trimmed extreme outlier DI values at 566,100 SEK, representing the 99th

BMJ Open

percentile of annual DI across all study years. This made the distribution of DI reasonably normal for statistical analyses. Individuals with missing values in LISA for DI and the secondary outcome variables, in years other than T_{0} , were excluded in descriptive statistics for the respective years, but were included in the GEE model. We capped earnings at the 99th percentile to control for extreme outliers, which resulted in a maximum possible annual value of 810,400 SEK.

Descriptive statistics were performed to describe the distribution of sociodemographic variables and summarise the levels of the different income variables. Categorical data were expressed as frequency distributions with the number and percentage. Continuous data were reported for both the PwMS and the reference group, expressed by the mean, standard deviation and both the number and proportion with annual sums >0.

The means of annual DI of PwMS was calculated for each year, $T_{.7}$ to T_{+4} . The differences in mean annual DI of PwMS were tested for statistical significance by dependent *t*-tests between the following three time points: $T_{.7}$ to T_0 ; T_0 to T_{+4} ; and $T_{.7}$ to T_{+4} . Independent two-tailed t-tests with Cochran approximation for the unequal variance were performed for each year of follow-up to test the difference in mean annual DI between PwMS and the references. The mean differences in annual sums of earnings, SA benefits, and DP benefits between PwMS and references were calculated at three time points: $T_{.7}$; T_0 ; and T_{+4} .

Lastly, we conducted linear regression analyses, using the generalised estimating equation (GEE) method to gain insight on how MS influenced the DI trajectory development over the study period.[36] The GEE model described the difference in the slopes of the DI trajectories from 2002 to 2013 between PwMS and the reference group as the method allowed for the dependent repeated measures of DI by accounting for the clustering of observations at both the individual and group levels that violated the independence assumptions of other methods. [36-38] The dependent variable, DI, was analysed as a continuous measure. The DI distribution was slightly right skewed, but GEE is a robust method.[37] The GEE model was computed with the following specifications: a normal distribution; identity link; and autoregressive within-subject correlation. The within-subject correlation structure BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

was selected because of the reasonable assumption that the correlation between an individual's annual DI values diminished over time. The models were adjusted for gender, age, education level, and country of birth. An additional age variable was included to account for curvilinearity. All variables were entered simultaneously with an interaction term of MS and year to evaluate whether PwMS had a different DI trajectory than the reference population. The periods pre and post diagnosis were assessed in separate models. The GEE model results were presented as un-standardised Beta regression coefficients with 95% confidence intervals (CI), which can be interpreted as values in SEK. The significance level for all analyses was $\alpha = 0.05$.

3 RESULTS

We observed growth of annual DI experienced by both the PwMS and the reference group over the
study period. There were significant differences between PwMS and the reference group in mean
annual sums of SA benefits, DP benefits and earnings along the disease trajectory, but there were no
differences in either the levels or development of mean annual DI between T₋₇ and T₊₄.

Table 1 contains a basic description of the study population and shows that the reference group (n= 7847) was representative of the PwMS cohort (n=785) on the distribution of these sociodemographic variables. The descriptive results revealed that the PwMS diagnosed in 2009 had a mean age of 41 (95% CI: 40.7-42.0). The cohort had a female to male ratio of 2.17. At the end of follow-up, T_4 , there were 97.3% (n=764) PwMS and 97.8% (n=7671) references with data available in LISA.

			1	Refere	nces ^b
		(%		n	(%)
	Sex	785	(100)	7847	(100)
	Men	248	(31.6)	2480	(31.6)
	Women	537	(68.4)	5367	(68.4)
	Age Group		()		()
	25-34	213	(27.1)	2130	$(27.1)^{3}$
	35-44	279	(35.5)	2790	(35.6)
	45-54	208	(26.5)	2077	(26.5)
	55-64	85	(10.8)	850	$(10.8)^{3}$
	Education (in years)		(10.0)		(-0.0)
	≤ 9 (elementary) ^c	111	(14.1)	1107	(14.1)
	10 -12 (high school)	355	(45.2)	3550	$(45.2)^{3}$
	>12 (college or university)	319	(43.2)	3190	(43.2) $(40.7)^{3}$
	Country of Birth	517	(40.0)	5170	(+0.7)
	Sweden	677	(86.2)	6770	(86.3)
	Nordic countries (except Sweden)	23	(86.2) (2.9)	230	(86.3) $(2.9)^3$
	EU25 (except Nordics)				
		27	(3.4)	270	(3.4)
	Rest of the world ^c ^a Reference group matched to MS cohor	58	(7.4)	577	(7.4)
	^b MS: Multiple sclerosis (MS) diagnosis specialised out-patient registers. Referen with no registered MS diagnosis in year ^c Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
31	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
31 32	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ntegory (<0.5	listribution % of both s	(1→10)
	specialised out-patient registers. Referent with no registered MS diagnosis in year 'Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ategory (<0.5	listribution % of both s	(1→10) study
	specialised out-patient registers. Referent with no registered MS diagnosis in year ' Individuals with missing variables add cohorts).	nces: matched s before 2010.	on variable d ategory (<0.5	listribution % of both s	(1→10) study
	specialised out-patient registers. Referent with no registered MS diagnosis in year ' Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ategory (<0.5	listribution % of both s	(1→10) study
	specialised out-patient registers. Referent with no registered MS diagnosis in year ' Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ategory (<0.5	listribution % of both s	(1→10) study
	specialised out-patient registers. Referent with no registered MS diagnosis in year ' Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ategory (<0.5	listribution % of both s	(1→10) study
	specialised out-patient registers. Referent with no registered MS diagnosis in year ' Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ategory (<0.5	listribution % of both s	(1→10) study
	specialised out-patient registers. Referent with no registered MS diagnosis in year ' Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ategory (<0.5	listribution % of both s	(1→10) study
	specialised out-patient registers. Referent with no registered MS diagnosis in year ' Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ategory (<0.5	listribution % of both s	(1→10) study
	specialised out-patient registers. Referent with no registered MS diagnosis in year ' Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ategory (<0.5	listribution % of both s	(1→10) study
	specialised out-patient registers. Referent with no registered MS diagnosis in year ' Individuals with missing variables add cohorts).	nces: matched s before 2010. ed to lowest ca	on variable d ategory (<0.5	listribution % of both s	(1→10) study

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

In T_0 , PwMS had a mean annual DI of 177,000 SEK (95% CI: 170,200-183,900) (Figure 1). PwMS experienced a mean increase in annual DI over the 12-year study period of 51,400 SEK (95% CI: 43,330-59,510). This increase in mean annual DI was observed in both the periods before (32,360 SEK, 95% CI: 26,360-38,360) and after diagnosis (19,390 SEK, 95% CI: 12,760-26,010) by dependent t-tests. While there was a steady increase in mean annual DI throughout the study, the distribution of annual DI of PwMS widened over follow-up.

To further investigate the mean annual DI of PwMS, comparison was made to the reference group. Figure 2 suggests there were differences in mean annual DI between PwMS and the reference group, where the reference group consistently had higher annual DI means, starting from four years prior to MS diagnosis. The gap between PwMS and references mean annual DI widened over time. However, independent t-tests revealed that these differences were statistically non-significant (not presented).

Table 2 displays the differences in the mean annual sums of the main components of DI (earnings, SA benefits, and DP benefits) between PwMS and references in $T_{.7}$, T_0 , and T_{+4} . In every year, both SA and DP had a median of zero; indicating that most individuals in both groups did not receive either benefit (not presented). The proportion of PwMS who received SA or DP increased over time, which resulted in a higher proportion of PwMS than references receiving these morbidity-related benefits. Accordingly, in every year, the mean SA and DP amounts were higher for PwMS than for the reference group. These mean differences were highly significant, apart from SA benefits in 2002 (T_{-7}). From the time of diagnosis T₀, PwMS had significantly lower earnings than the reference group.

\overline{A}	1 2 3	253 254	Table 2: Annual mea	n components	of disp r
6 Mean sum (100 SEK*) Deck Deck 9 $T_{.7}$ 10 Sickness absence 108 11 Disability pension 140 14 12 Earnings b 1842 14 13 Disposable income b 1491 16 14 Disposable income b 1491 16 15 T_0 Sickness absence 267 16 16 Sickness absence 267 16 17 Disability pension 136 16 18 Disposable income b 1770 9 20 Tr4 23 Sickness absence 292 16 21 Tr4 10 Sickness absence 292 16 22 Tr4 10 Sickness absence 292 16 23 Disability pension 293 16 17 16 24 Disposable income b 1994 16 16 16 16 25 Earnings b 2144 16 16 16 16 16					Ν
7 (100 SEK*) Dev 9 $T_{.7}$ 10 Sickness absence 108 11 Disability pension 140 3 12 Earnings b 1842 1 13 Disposable income b 1491 0 16 T_0 Sickness absence 267 3 16 T_0 Sickness absence 267 3 17 Disability pension 136 3 3 20 Disposable income b 1770 9 21 T_{r4} 3 3 3 22 T_{r4} 3 3 3 3 23 Sickness absence 292 3 3 3 3 24 Disposable income b 1994 1 10 10 10 10 24 Disposable income b 1994 1 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	6			Mean sum	S
9 $T_{.7}$ 10 Sickness absence 108 11 Disability pension 140 13 Earnings b 1842 1 14 Disposable income b 1491 0 15 T_0 136 13 16 Sickness absence 267 16 17 Disability pension 136 13 18 Disposable income b 1770 9 20 T+4 10 13 14 21 T-4 14 14 16 22 T+4 16 1770 9 14 23 Sickness absence 292 14 16 24 Disposable income b 1994 16 16 25 Earnings b 2144 14 16 27 Disposable income b 1994 16 28 Inflated to 2016 Swedish Krona (SEK) w 16 31 variable distribution (1→10) with no regis 16 32 14 14 14 14 <tr< th=""><th></th><th></th><th></th><th>(100 SEK^a)</th><th>Dev</th></tr<>				(100 SEK ^a)	Dev
10 Sickness absence 108 11 12 Disability pension 140 14 13 Disposable income b 1491 14 14 Disposable income b 1491 16 15 T_0 Sickness absence 267 16 16 Sickness absence 267 16 17 Disposable income b 1770 16 20 T_{+4} Sickness absence 292 16 21 Disposable income b 1770 17 17 22 T_{+4} Sickness absence 292 18 23 Sickness absence 292 14 16 24 Disposable income b 1994 14 16 27 Disposable income b 1994 14 16 28 Earnings b 2144 16 29 Frimmed at the 99 percentile. Number count or proportion receiving an c			T7		
12 Disability pension 140 140 13 Earnings b 1842 1 14 Disposable income b 1491 0 15 T_0 136 136 16 Sickness absence 267 136 19 Earnings b 2078 1 20 Disposable income b 1770 0 21 T_{+4} 172 136 22 T_{+4} 10 136 14 23 Sickness absence 292 14 16 24 Disposable income b 1994 1 19 25 Earnings b 2144 14 14 26 Earnings b 2144 14 14 27 Disposable income b 1994 14 14 28 * Inflated to 2016 Swedish Krona (SEK) v. 16 17 16 31 extrabulation (1 \rightarrow 10) with no regist of Number count or proportion receiving an count or proportion receiving an count or $T_{-7} = 2002, T_0 = 2009$ and $T_{-4} = 2013. 16 17 33 256 14$			Sickness absence	108	3
13 Earnings b 1842 1 14 Disposable income b 1491 0 15 T_0 Sickness absence 267 3 19 Earnings b 2078 1 20 Disability pension 136 3 21 T_{+4} 3 3 3 22 T_{+4} 3 3 3 23 Sickness absence 292 3 3 24 Disposable income b 1770 9 3 3 26 Earnings b 2144 1 1 27 Disposable income b 1994 1 1 28 Earnings b 2144 1 1 29 brinflated to 2016 Swedish Krona (SEK) v b b brimmed at the 99 percentile. 6 33 $^{\circ}$ T.7 = 2002, T_0 = 2009 and T_{+4} = 2013. 3 3 3 3 36 255 3 3 3 3 3 3 3 3 3 3 3 3 3 3			Disability pension	140	5
14 Disposable income b 1491 1491 15 T ₀ 16 Sickness absence 267 18 Disability pension 136 136 19 Earnings b 2078 1 20 T_{+4} 23 Sickness absence 292 1 21 T_{+4} 23 Sickness absence 292 24 23 Sickness absence 292 24 10 10 24 Disposable income b 1994 1 10 14 11 25 Earnings b 2144 1 10 10 14 11 27 Disposable income b 1994 1 14 14 14 28 Earnings b 2144 1 14 <t< td=""><td></td><td></td><td>Earnings ^b</td><td>1842</td><td>15</td></t<>			Earnings ^b	1842	15
16 I_0 17 Sickness absence 267 18 Disability pension 136 19 Earnings b 2078 1 20 I_{+4} 1 1 21 I_{+4} 1 1 22 I_{+4} 1 1 23 Earnings b 2144 1 24 Disability pension 293 3 26 Earnings b 2144 1 27 Disability pension 293 3 26 Earnings b 2144 1 27 Disability pension 293 3 28 Frimmed at the 99 percentile. * 10 30 * Multiple sclerosis (MS) diagnosis fi 10 31 * T.7 = 2002, T_0 = 2009 and T_{+4} = 2013. 3 36 255 3 3 36 256 3 3 36 256 3 3 37 38 256 3 38 256 3 3			Disposable income ^b	1491	6
17 Sickness absence 267 18 Disability pension 136 19 Earnings b 2078 1 20 T+4 1 21 T+4 1 22 T+4 1 23 Sickness absence 292 2 24 Disability pension 293 2 25 Earnings b 2144 1 26 Disposable income b 1994 1 27 Disposable income b 1994 1 28 Farnings b 2144 1 29 Sickmess absence 1994 1 28 Farnings b 2144 1 29 Farnings date the 99 percentile. 100 100 100 30 Trimmed at the 99 percentile. 100 100 100 100 31 255 37 266 255 37 38 256 33 256 39 400 41 422 43 444 45			T ₀		
18 Disability pension 136 136 19 Earnings b 2078 1 20 T_{+4} 1 22 T_{+4} 1 23 Sickness absence 292 1 24 Disability pension 293 1 25 Earnings b 2144 1 26 Disability pension 293 1 26 Earnings b 2144 1 27 Disposable income b 1994 1 28 Finlated to 2016 Swedish Krona (SEK) w b 30 * Inflated to 2016 Swedish Krona (SEK) w b 31 * Sickness absence 292 1 32 MS: Multiple sclerosis (MS) diagnosis find with no regist m 33 * T.7 = 2002, T_0 = 2009 and T_{+4} = 2013. 1 34 256 1 1 35 255 1 1 36 255 1 1 37 256 1 1 38 256 1 1 39 <td>-</td> <td></td> <td>Sickness absence</td> <td>267</td> <td>5</td>	-		Sickness absence	267	5
20 Disposable income b 1770 9 22 T_{+4} 3 3 3 23 Sickness absence 292 4 23 Disability pension 293 5 24 Disposable income b 1994 1 25 Earnings b 2144 1 26 Disposable income b 1994 1 27 Disposable income b 1994 1 28 Inflated to 2016 Swedish Krona (SEK) volume b 30 b Trimmed at the 99 percentile. c MS: Multiple sclerosis (MS) diagnosis fi 31 variable distribution (1 \rightarrow 10) with no regis d Number count or proportion receiving an c T.7 = 2002, T_0 = 2009 and T_{+4} = 2013. 35 36 255 37 38 256 39 40 41 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59			Disability pension	136	3
21 Disposable income 10 $17/0$ 22 T_{+4} 23 Sickness absence 292 24 Disability pension 293 25 Earnings b 2144 1 27 Disposable income b 1994 1 28 Earnings b 2144 1 29 b Inflated to 2016 Swedish Krona (SEK) v b Trimmed at the 99 percentile. c MS: Multiple sclerosis (MS) diagnosis fi 30 b Trimmed at the 99 percentile. c MS: Multiple sclerosis (MS) diagnosis fi 31 a Number count or proportion receiving an 33 d Number count or proportion receiving an 34 c T. $_{7}$ = 2002, T $_{0}$ = 2009 and T $_{+4}$ = 2013. 35 256 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 59 <td>19</td> <td></td> <td>Earnings ^b</td> <td>2078</td> <td>17</td>	19		Earnings ^b	2078	17
22 T_{+4} 23 Sickness absence 292 24 Disability pension 293 25 Earnings b 2144 1 27 Disposable income b 1994 1 28 Inflated to 2016 Swedish Krona (SEK) v b 29 b Trimmed at the 99 percentile. ° MS: Multiple sclerosis (MS) diagnosis fi 30 b Trimmed at the 99 percentile. ° MS: Multiple sclerosis (MS) diagnosis fi 31 variable distribution (1→10) with no regis ° Number count or proportion receiving an 33 c T.7 = 2002, T_0 = 2009 and T_{+4} = 2013. S 36 255 37 38 256 39 40 41 42 43 44 45 46 47 48 49 50 51 53 54 55 56 57 58 59 59 50			Disposable income ^b	1770	9
23 Sickness absence 292 323 24 Disability pension 293 323 26 Earnings b 2144 11 27 Disposable income b 1994 11 28 a Inflated to 2016 Swedish Krona (SEK) w 29 b Trimmed at the 99 percentile. 30 b Trimmed at the 99 percentile. 31 a MS: Multiple sclerosis (MS) diagnosis fills 32 d Number count or proportion receiving and 33 c $7.7 = 2002, T_0 = 2009$ and $T_{+4} = 2013.$ 36 255 37 38 256 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 59			T ₊₄		
25 26 27 28 29 30 31 32 33 34 35 36 255 37 38 256 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59			Sickness absence	292	5
26 Earnings b 2144 1 27 Disposable income b 1994 1 28 a Inflated to 2016 Swedish Krona (SEK) v. 29 b Trimmed at the 99 percentile. c 30 b Trimmed at the 99 percentile. c 31 c MS: Multiple sclerosis (MS) diagnosis fi variable distribution (1 \rightarrow 10) with no regis d 33 d Number count or proportion receiving an c T.7 = 2002, T_0 = 2009 and T_{+4} = 2013. 36 255 37 38 256 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 59 59 50 51			Disability pension	293	5
27 Disposable income b 1994 1 28 a Inflated to 2016 Swedish Krona (SEK) v. 29 b Trimmed at the 99 percentile. a 30 c MS: Multiple sclerosis (MS) diagnosis fivariable distribution $(1 \rightarrow 10)$ with no registed a Number count or proportion receiving and a transition of the experimental e			Earnings ^b	2144	19
29 30 31 32 33 34 34 35 36 255 37 38 256 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 50 51 52 53 54 55 56 57 58 59			Disposable income ^b	1994	11
30 b Trimmed at the 99 percentile. 31 c MS: Multiple sclerosis (MS) diagnosis fivariable distribution $(1 \rightarrow 10)$ with no regis 33 a Number count or proportion receiving an 34 c T.7 = 2002, T0 = 2009 and T+4 = 2013. 36 255 37 38 38 256 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 59			^a Inflated to 2016 Swe	dish Krona (SI	EK) va
35 36 255 37 38 256 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	31 32		^c MS: Multiple scleros variable distribution (^d Number count or pro	sis (MS) diagno $1 \rightarrow 10$) with no portion receivi	regist ng anr
36 255 37 38 256 39 40 41 41 42 43 43 44 45 46 47 48 49 50 51 50 51 52 53 54 55 56 57 58 59 59 50			$^{\circ}$ T ₋₇ = 2002, T ₀ = 2009	9 and $T_{+4} = 202$	13.
37 38 256 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		255			
39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		200			
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		256			
42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59					
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59					
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59					
46 47 48 49 50 51 52 53 54 55 56 57 58 59					
47 48 49 50 51 52 53 54 55 56 57 58 59					
48 49 50 51 52 53 54 55 56 57 58 59					
50 51 52 53 54 55 56 57 58 59					
51 52 53 54 55 56 57 58 59					
52 53 54 55 56 57 58 59					
54 55 56 57 58 59					
55 56 57 58 59					
56 57 58 59					
58 59					
59					
	60		For p	eer review o	nly -

Table 2: Annual mean components of disposable income (DI) for the cohort of people with MS (N=785) and the cohort of	
references (N=7847) at $T_{.7}$, T_0 and T_{+4}^{e}	

	MS [°]				References ^c				Mean	<i>p</i> -value
	Mean sum (100 SEK ^a)	Std Deviation	n ^d	⁰⁄₀ ^d	Mean sum (100 SEK ^a)	Std Deviation	n ^d	% ^d	difference (100 SEK ^a)	for difference
T ₋₇			747				7457			
Sickness absence	108	342	147	20	85	273	1289	17	23	0.078
Disability pension	140	513	63	8	84	348	383	5	56	0.004
Earnings ^b	1842	1598	645	86	1939	1566	6653	89	-97	0.1
Disposable income ^b	1491	679	-	-	1501	697	-	-	-10	0.686
T ₀			785				7847			
Sickness absence	267	500	347	44	40	202	811	10	227	0.001
Disability pension	136	382	103	13	86	316	629	8	50	0.001
Earnings ^b	2078	1771	651	83	2484	1718	6791	87	-405	0.001
Disposable income ^b	1770	981	-	-	1820	1025	-	-	-50	0.178
T ₊₄			764				7671			
Sickness absence	292	553	220	29	79	305	963	13	213	0.001
Disability pension	293	553	210	28	79	305	558	7	214	0.001
Earnings ^b	2144	1928	582	76	2793	1895	6719	88	-649	0.001
Disposable income ^b	1994	1100	-	-	2055	1117	-	-	-61	0.1

alues by the Harmonised Consumer Price Index. In 2017, 100 SEK \approx 10.5 Euros.

rst registered in 2009 in national in- and specialised out-patient registers. References: matched on tered MS diagnosis in years before 2010.

nual sums > 0.

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

Potential differences in the development of the mean annual DI trajectory of PwMS from that of the matched references were assessed with a GEE model. In Figure 2, there were indications of the slopes both diverging prior to diagnosis and realigning to develop more in parallel in the years after diagnosis. All results from the GEE model provided non-significant differences between the development of the DI trajectories of PwMS and the reference group. Table 3 contains the differences in DI development after diagnosis in relation to the year of diagnosis and shows that between T_0 and T_{+4} was on an average 781 SEK (95% CI: -6922-3133) less for PwMS than for the reference group. Analysis of the pre-diagnosis period is contained in Table 4, where from $T_{.7}$ to T_0 the development of mean annual DI for PwMS was on an average 4039 SEK (95% CI:-10,536 -3315) lower than the WMS ... reference group.

269 Table 3: Disposable Income (DI) trajectory post diagnosis from T_0 (2009) to T_{+4} (2013) in the cohort of people with MS 270 (N=785) compared to the cohort of references (N=7847) ^{ab}

adjusted regression coefficient ^{cde}	95% CI ^e
-7.81	-69.22-31.33
16.23	-38.39-27.87
12.00	-41.20-27.14
17.10	-32.26-25.19
e sclerosis (MS) diagnosis first i lised out-patient registers, n=783	registered in 2009 in national 5 in 2009. References: matched
	coefficient ^{cde} -7.81 16.23 12.00

before and including 2009, n=7847 in 2009. ^c Adjusted for age, gender, education level and country of birth. ^d Un-standardised beta. Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK \approx 10.5 Euros. ^e 100 SEK.

Table 4: Disposable Income (DI) trajectory prior to diagnosis from $T_{.7}$ (2002) to T_0 (2009) in the cohort of people with MS (N=785) compared to the cohort of references (N=7847)^{ab}

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright.

Year	adjusted regression coefficient ^{c d e}	95% CI °
2009	-40.39	-105.36-33.15
2008	3.04	-61.35-32.85
2007	-7.14	-68.83-31.47
2006	-20.60	-75.88-28.20
2005	-8.63	-60.85-26.64
2004	2.58	-46.80-25.20
2003	-15.15	-48.44-16.98
^b MS: Multiple sc national in- and s References: matc MS diagnosis in y ^c Adjusted for ago ^d Un-standardisec	bs for analysis: 2002 (T.7) and elerosis (MS) diagnosis first re pecialised out-patient registers hed on variable distribution (1 years before 2010, n=7847 in 2 e, gender, education level and 1 beta. Inflated to 2016 Swedis Consumer Price Index. In 2017	gistered in 2009 (T_0), in $rac{1}{3}$ m=785 in 2009. \rightarrow 10) with no registered 2009. country of birth. h Krona (SEK) values by

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

278 4 DISCUSSION

279 4.1 Principal findings

We have presented the mean DI development for PwMS from seven years prior to four years after diagnosis, in comparison to the trajectory of a population-based stratified matched reference group without MS. This is the first Swedish study to analyse the DI trajectory of PwMS, and builds upon previous research of the individual components of DI. Our principal finding was that within the first four years after diagnosis there was little change to PwMS' DI trajectory in comparison to those without MS. Both groups' trajectories developed in parallel despite significant differences for individual component sources of income: earnings; SA benefits; and DP benefits. The morbidity-related benefits balanced the expected gap from reduced earnings to maintain the economic welfare of PwMS. The result that both DI levels and development are similar can be plausibly interpreted as the Swedish welfare system is responsive to the economic consequences of work incapacity through the SA and DP benefits around diagnosis with MS.

291 4.2 Interpretation of findings in context of previous research

To situate our findings on DI, distinct differences in the levels of mean annual gross income (earnings and benefit payments, but excluding SA benefits) were found in a Danish study by Hilt Pfleger et al, where 20-years after diagnosis, PwMS received 70% of the mean annual gross income of matched references.[22] The difference was attributed to DP benefits becoming the dominating source of income for PwMS in this longer follow-up, and compensated as a proportion of previous earnings.[22] Similarly to our results, Hilt Pfleger et al. found that both PwMS and references prior to diagnosis had an almost equal level of gross income.[22] Notable differences between the Danish and Swedish social security systems exist, for example, the lengths and entitlements for SA benefits and transition to DP benefits.[39] However, they are similar enough that it is likely that a longer follow-up period in our study would have reflected some differences in mean annual DI as found by Hilt Pfleger et al., especially as previous research in Sweden, albeit non-specific on diagnosis, suggested that SA benefits were associated with lower subsequent DI levels.[20 22]

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

In line with previous research, we identified a larger proportion of PwMS receiving income from morbidity-related benefits than references.[3 13 40] Trends from previous findings were reflected in the increased proportions of PwMS receiving DP benefits along the disease trajectory.[19 40] SA benefits are designed to compensate periods of temporary absence from work, and following the progressive chronic characteristics of MS, permanent DP can be expected to increase with time.[3 14 19 40] We observed DP surpassing SA benefits four years post-diagnosis. This shift should plausibly reduce DI development because DP is compensated at a lower rate than SA. Such patterns were not found for the reference group; the proportions of references receiving SA benefits were larger than DP for all years.

Similarly to Wiberg et al., we found that PwMS had lower mean annual earnings than the references from diagnosis, with the mean difference increasing as the disease progressed.[3] This trend of increasing heterogeneity of PwMS' earnings has been postulated to be due to the disparate levels of work incapacity influenced by symptom severity, and variations in workplace and occupation flexibility to adapt. [15 29 41] Pearson et al. suggested ill health may reduce the level of earnings of those who remain economically active due to truncated careers and underemployment.[12] Therefore, further changes can be expected as time from diagnosis advances.[12 40] Both Wiberg et al. and our findings show that despite changes in income sources, earnings remain the dominating income source for PwMS; 76% of the PwMS in our study remained in paid work 4 years after diagnosis.[3] Hilt Pfleger et al., remarked that PwMS maintained similar levels of gross income to the references if remaining in paid work, which supports our finding of similar DI trajectories.[22]

324 4.3 Strengths and limitations

A distinctive characteristic of this explorative study that adds to its strength and external validity was the use of nationwide registers. The registers provided the most complete data available and enabled both full inclusion of incident cases and use of DI. Larger study populations have been observed in prevalence-based studies; however, such designs were incompatible with our aim. Our study reflects common methodological characteristics of register-based income studies of PwMS. Formal diagnosis

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

by ICD code was indicative of MS status, and despite the possibility for miscoding. ICD codes remain more objective than the alternative, onset of symptoms, which suffer inaccuracies from recall bias and attribution to MS.[40 42] The longitudinal design included both pre- and post-diagnosis periods, to observe earlier progressive aspects of MS prior to diagnosis, such as relapses and resultant changes in income sources.[4] Limitations of our study include that short SA spells (<14 days) were missing and the SA analyses may therefore be underestimated. However, the DI analyses were unaffected, as these days were included within the composite indicator under earnings because such spells are usually employer

compensated except for the first uncompensated day. Our analyses assumed homogeneity within PwMS and did not consider the variation by either sociodemographic or disease characteristics. An additional assumption in our interpretation of economic welfare was that DI was distributed evenly within households according to need, but the actual distribution of income within households was unknown. [27 30] Further, some informal support by increased earnings of household members was er.e also plausible.

4.5 Implications for policy and research

MS was not associated with economic welfare in Sweden. This suggests that the morbidity-related transfer payments buffered the economic consequences of MS as the disease progressed around diagnosis, compensating for the reduced earnings to ensure unchanged levels and development of the DI trajectory [28 43] Our results reflect the combination of a responsive welfare system and the incremental progression of MS morbidity. Furthermore, our study provides support to the suggestion that the effect of health status on income is less pronounced than the relationship's reciprocal direction within welfare state contexts.[44] As the disease progresses, differences in DI trajectories may become more apparent and reflect the findings of Hilt Pfleger et al. [22] Current focus of MS treatment is on early intervention to delay disease progression, which should further preserve work capacity.[15 42] Our results suggest that society is bearing some of the economic burden associated with MS, which the individual would otherwise experience. The observation that the economic situation does not seem

BMJ Open

to differ much between the groups implies that that the flexible system of morbidity-related benefits that differentiate morbidity situations and levels of work incapacity is necessary for PwMS to maintain similar levels of economic welfare to the general population along the disease trajectory, as there are no curative treatment options available.

Future research is required as unanswered questions remain; we did not have the opportunity to capture DI changes that may occur as MS progresses further from diagnosis. Additionally, future studies should be designed to investigate whether DI trajectories of PwMS are patterned by sociodemographic characteristics or disease severity.

365 5. CONCLUSIONS

Our results indicate that PwMS as a group have similar DI growth to those without MS in Sweden. We found significant differences between PwMS and the population-based reference group in the proportions receiving and levels of individual income sources along the disease trajectory. However, no differences were found in the levels or development of the composite measure, annual DI, at least for the first four years post-diagnosis. In line with its intentions, the welfare system appears to be responsive to the individuals' economic welfare through the balancing of reduced annual earnings by compensation with the SA and DP benefits.

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

Author Statement: PT, MW, KK, CM and OM participated in the design of the study. MW, OM and CM performed data management, and MW, OM, CM and PT were involved in the data analyses. All authors (CM, OM, MW, KA, KK, EF and PT) contributed to interpretation of results, participated in the writing and reviewing of the drafts, and have approved the final version of the manuscript.

Competing interests statement: We have read and understood the BMJ policy on declaration of interests. All authors have completed the ICMJE uniform disclosure at www.icmje.org/coi disclosure.pdf and declare the following interests with respect to the research, authorship, and/or publication of this article: CM, PT, EF, and MW received financial support from Biogen for the submitted work. KA has received unrestricted research grants from Biogen. OM and KK had no competing interests to declare.

Funding: This work was supported by Biogen and the Swedish Research Council for Health, Working Life and Welfare. The design of the study, data collection, analyses, interpretations of data, and writing of manuscript was performed without involvement of the funding bodies.

Data Statement: No additional data available. The authors of this study are not permitted to make the micro-level data in this study publically available due to its sensitive nature. According to the Swedish Ethical Review Act, the Personal Data Act, and the Administrative Procedure Act, data can be made available after legal review for researchers who meet the criteria for access to this type of sensitive and confidential data. For questions about this, please contact Professor Kristina Alexanderson, responsible for the data set.

BMJ Open

1		
2	400	DEFEDENCES
3	400	REFERENCES
4	401	
5	402	1. Fattore G, Lang M, Pugliatti M. The Treatment experience, burden, and unmet needs (TRIBUNE)
6	403	study - measuring the socioeconomic consequences of Multiple Sclerosis. Multiple Sclerosis
7	404	Journal 2012;18(2 Suppl):5-6 doi: 10.1177/1352458512447262[published Online First: Epub
8	405	Date]].
9	406	2. Ahlgren C, Oden A, Lycke J. High Nationwide Incidence of Multiple Sclerosis in
10	407	Sweden. PloS one 2014; 9 (9):e108599
11	408	3. Wiberg M, Friberg E, Stenbeck M, et al. Sources and level of income among individuals with
12	409	multiple sclerosis compared to the general population: A nationwide population-based study.
13	410	Multiple Sclerosis Journal 2015; 21 (13):1730–41 doi: 10.1177/1352458515570767[published
14	411	Online First: Epub Date].
15	412	4. Mills E, Mirza A, Mao-Draayer Y. Emerging approaches for validating and managing multiple
16	413 414	sclerosis relapse. Frontiers in Neurology 2017;8(116) doi: 0.3389/fneur.2017.00116[published
17	414	Online First: Epub Date]. 5. Duddy M, Haghikia A, Cocco E, et al. Managing MS in a changing treatment landscape. Journal of
18	415	neurology, neurosurgery, and psychiatry 2011; 258 (5):728-39 doi: 10.1007/s00415-011-6009-
19	410	x[published Online First: Epub Date].
20	417	6. Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden.
21	418	The European journal of health economics : HEPAC : health economics in prevention and
22	419	care 2006 7:S75–S85 doi: 10.1007/s10198-006-0379-5[published Online First: Epub Date] .
23	420	7. Krause I, Kern S, Horntrich A, et al. Employment status in multiple sclerosis: impact of disease-
24	422	specific and non-disease-specific factors. Multiple Sclerosis Journal 2013;19(13):1792–99 doi:
25	423	10.1177/1352458513485655[published Online First: Epub Date]].
26 27	424	8. Moore P, Harding K, Clarkson H, et al. Demographic and clinical factors associated with changes in
27	425	employment in multiple sclerosis. Multiple Sclerosis Journal 2013;9(12):1647–54 doi:
28	426	10.1177/1352458513481396[published Online First: Epub Date]].
29 30	427	9. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in
30 31	428	Europe. Journal of neurology, neurosurgery, and psychiatry 2006;77:918-26 doi:
32	429	10.1136/jnnp.2006.090365[published Online First: Epub Date]].
32 33	430	10. Smith M, Arnett P. Factors related to employment status changes in individuals with multiple
33 34	431	sclerosis. Multiple Sclerosis Journal 2015;11(5):602-09 doi:
35	432	10.1191/1352458505ms1204oa[published Online First: Epub Date]].
36	433	11. Moore P, Harding K, Clarkson H, et al. Demographic and clinical factors associated with changes
37	434	in employment in multiple sclerosis. Multiple Sclerosis Journal 2013;19(12):1647-54 doi:
38	435	10.1177/1352458513481396[published Online First: Epub Date].
39	436	12. Pearson J, Alla S, Clarke S, et al. Multiple Sclerosis impact on employment and income in New
40	437	Zealand. Acta neurologica Scandinavica 2017; 136 (3):223–32 doi:
41	438	10.1111/ane.12714[published Online First: Epub Date].
42	439	13. Gyllensten H, Wiberg M, Alexanderson K, et al. How does work disability of patients with MS
43	440	develop before and after diagnosis? A nationwide cohort study with a reference group. BMJ
44	441	open 2016;6(11):e012731 doi: 10.1136/bmjopen-2016-012731[published Online First: Epub
45	442	Date] .
46	443	14. Gyllensten H, Wiberg M, Alexanderson K, et al. Costs of illness of multiple sclerosis in Sweden: a
47	444	population-based register study of people of working age. The European journal of health
48	445	economics : HEPAC : health economics in prevention and care 2017:1-12 doi:
49	446	10.1007/s10198-017-0894-6[published Online First: Epub Date] .
50	447	15. Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis
51	448	in Europe. Multiple sclerosis 2017; 23 (8):1123-36 doi: 10.1177/1352458517694432[published
52	449	Online First: Epub Date].
53	450	16. Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis: a systematic review of
54	451 452	the literature. Pharmacoeconomics 2010; 28 (5):363-79 doi: 10.2165/11532230-000000000-00000000000000000000000
55	452	00000[published Online First: Epub Date] .
56		
57		
58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

17. Fritzell J, Nermo M, Lundberg O. The impact of income: assessing the relationship between income and health in Sweden. Scandinavian journal of public health 2004:32(1):6-16 doi: 10.1080/14034950310003971[published Online First: Epub Date]|. 18. Solar O, Irwin A. A conceptual framework for action on the social determinants of health. Social Determinants of Health Discussion Paper 2 (Policy and Practice). . Geneva: World Health Organization, 2010. 19. Chruzander C, Tinghög P, Ytterberg C, et al. Longitudinal changes in sickness absence and disability pension, and associations between disability pension and disease-specific and contextual factors and functioning, in people with multiple sclerosis. Journal of the neurological sciences 2016;367:319-25 doi: 10.1016/j.jns.2016.05.055[published Online First: Epub Date]|. 20. Wiberg M, Friberg E, Palmer E, et al. Sickness absence and subsequent disposable income: A population-based cohort study. Scandinavian journal of public health 2015;43(4):432-40 doi: 10.1177/1403494815575341[published Online First: Epub Date]]. 21. Glad S, Nyland H, Aarseth J, et al. How long can you keep working with benign multiple sclerosis? Journal of neurology, neurosurgery, and psychiatry 2011;82(1):78-82 doi: 10.1136/jnnp.2010.210732[published Online First: Epub Date]]. 22. Pfleger C, Flachs E, Koch-Henriksen N. Social consequences of multiple sclerosis (1): early pension and temporary unemployment--a historical prospective cohort study. Multiple sclerosis 2010;16(1):121-6 doi: 10.1177/1352458509352196[published Online First: Epub Date]. 23. Jennum P, Wanscher B, Frederiksen J, et al. The socioeconomic consequences of multiple sclerosis: a controlled national study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2012:22(1):36-43 doi: 10.1016/j.euroneuro.2011.05.001[published Online First: Epub Date]|. 24. Davey Smith G, Hart C, Hole D, et al. Education and occupational social class: which is the more important indicator of mortality risk? Journal of epidemiology and community health 1998;**52**(3):153–60 25. Marmot M. The Influence Of Income On Health: Views Of An Epidemiologist. Health Affairs 2002;**21**(2):31-46 doi: 10.1377/hlthaff.21.2.31[published Online First: Epub Date]|. 26. Tinghög P, Hillert J, Kjeldgard L, et al. High prevalence of sickness absence and disability pension among multiple sclerosis patients: a nationwide population-based study. Multiple sclerosis 2013;19(14):1923-30 doi: 10.1177/1352458513488234[published Online First: Epub Date]. 27. Galobardes B. Shaw M. Lawlor D. et al. Indicators of socioeconomic position (part 1). Journal of epidemiology and community health 2006;60(1):7-12 doi: 10.1136/jech.2004.023531[published Online First: Epub Date]]. 28. Smith J. Healthy Bodies and Thick Wallets: The Dual Relation Between Health and Economic Status. J Econ Perspect 1999;13(2):144-66 29. Salter A, Thomas N, Tyry T, et al. Employment and absenteeism in working-age persons with multiple sclerosis. Journal of Medical Economics 2017;20(5):493-502 doi: 10.1080/13696998.2016.1277229[published Online First: Epub Date]]. 30. Galobardes B, Lynch J, Davey Smith G. Measuring socioeconomic position in health research. British medical bulletin 2007;81-82:21-37 doi: 10.1093/bmb/ldm001[published Online First: Epub Datell. 31. Gustafsson K, Aronsson G, Marklund S, et al. Peripheral labour market position and risk of disability pension: a prospective population-based study. BMJ open 2014;4(8):e005230 doi: 10.1136/bmjopen-2014-005230[published Online First: Epub Date]]. 32. Kavaliunas A, Wiberg M, Tinghög P, et al. Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients. PloS one 2015;10(12):e0145435 doi: 10.1371/journal.pone.0145435[published Online First: Epub Date]|. 33. Thormann A, Sørensen P, Koch-Henriksen N, et al. Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships. European journal of neurology 2017;24(6):825-34 doi: 10.1111/ene.13297[published Online First: Epub Date]|.

BMJ Open

34.	Statistika Centralbyrån. Bakgrundsfakta 2016:1 Longitudinell integrationsdatabas för Sjukförsäkrings- och Arbetsmarknadsstudier (LISA) 1990-2013. Örebro: Statistics Sweden, Population and Welfare Department, 2016.
35.	Statistika Centralbyrån. Konsumentprisindex (KPI) [Consumer price index]. Secondary Konsumentprisindex (KPI) [Consumer price index] 2016. <u>http://www.scb.se/hitta-statistik/statistik-efter-amne/priser-och-konsumtion/konsumentprisindex/konsumentprisindex-kpi/</u> .
36.	Liang K, Zeger S. Longitudinal Data Analysis Using Generalized Linear Models. Biometrika 1986;73(1):13-22
37.	Rahman S, Mittendorfer-Rutz E, Alexanderson K, et al. Disability pension due to common mental disorders and healthcare use before and after policy changes: A nationwide study Eur J Public Health 2017;27(1):90-96
	 Hanley J, Negassa A, Edwardes M, et al. Statistical Analysis of Correlated Data Using Generalized Estimating Equations: An Orientation. American Journal of Epidemiology 2003;157(4):364-75
	Mutual Information System on Social Protection (MISSOC). Your social security rights in Denmark. Secondary Your social security rights in Denmark July 2013 2013. ec.europa.eu/social/BlobServlet?docId=13746&langId=en.
	Landfeldt E, Castelo-Branco A, Svedbom A, et al. Sick leave and disability pension before and after diagnosis of multiple sclerosis. Multiple Sclerosis Journal 2016; 22 (14):1859–66 doi: 10.1177/1352458516667567[published Online First: Epub Date]].
41.	Earnings among multiple sclerosis patients compared to individuals without multiple sclerosis, in total and for different educational levels and types of occupations - a longitudinal-based cohort study. ECTRIMS 2015 7-10 October; Barcelona, Spain.
42.	Gyllensten H, Wiberg M, Alexanderson K, et al. Comparing costs of illness of multiple sclerosis in three different years: A population-based study. Multiple Sclerosis Journal 2017;[Epub ahead of print]:1-9 doi: 10.1177/1352458517702549[published Online First: Epub Date]].
43.	Davey Smith G, Blane D, Bartley M. Explanations for socio-economic differentials in mortality: Evidence from Britain and elsewhere. European Journal of Public Health 1994;4(2):130-44 doi: doi.org/10.1093/eurpub/4.2.131[published Online First: Epub Date]].
44.	Aittomaki A, Martikainen P, Laaksonen M, et al. Household economic resources, labour-market advantage and health problems - a study on causal relationships using prospective register data. Soc Sci Med 2012;75(7):1303-10 doi: 10.1016/j.socscimed.2012.05.015[published Online First: Epub Date]].

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

44. Aittomaki A, Martikainen P, Laaksonen M, et al. Household econor advantage and health problems - a study on causal relationship data. Soc Sci Med 2012;75(7):1303-10 doi: 10.1016/j.socsc Online First: Epub Date]. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 24 of 27

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright.

BMJ Open




Figure 1: Mean disposable income (DI) in 2002-2013 among people diagnosed with multiple sclerosis (MS) in 2009. Mean annual disposable (DI) sum labelled to the right with the 95% confidence interval illustrated. DI inflated to 2016 values in Swedish Krona (SEK) with Harmonised Consumer Price Index. In 2017, 100
 SEK ≈ 10.5 Euros. MS: individuals with first registered multiple sclerosis (MS) diagnosis in 2009 in national in- and specialised out-patient registers. Year of diagnosis (2009): dashed vertical line.

139x83mm (96 x 96 DPI)




Figure 2: Mean disposable income (DI) in 2002-2013 among people diagnosed with multiple sclerosis (MS) in 2009 (N= 785) compared to references (N=7847). Annual disposable income (DI) inflated to 2016 values in Swedish Krona (SEK) with Harmonised Consumer Price Index. In 2017, 100 SEK \approx 10.5 Euros. MS: individuals with first registered multiple sclerosis (MS) diagnosis in 2009 in national in- and specialised outpatient registers, solid line. References: matched on four variables (1 \rightarrow 10) with no MS diagnosis registered in years before 2010. Year of diagnosis (2009): dashed vertical line.

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright.

165x96mm (96 x 96 DPI)

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	ltem #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5-6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5, 7-9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	6&8
		(d) If applicable, explain how loss to follow-up was addressed	6&8
		(e) Describe any sensitivity analyses	N/A

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright.

BMJ Open

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed	9
		eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	6&9
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential	9 & 10
		confounders	
		(b) Indicate number of participants with missing data for each variable of interest	9
		(c) Summarise follow-up time (eg, average and total amount)	9
Outcome data	15*	Report numbers of outcome events or summary measures over time	11-12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence	13-14
		interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	15
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from	15-18
		similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on	18
		which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright.

BMJ Open

Trajectories of disposable income among people of working ages diagnosed with multiple sclerosis: A nationwide register-based cohort study in Sweden 7 years before to 4 years after diagnosis with a population-based reference group

Journal:	BMJ Open
Manuscript ID	bmjopen-2017-020392.R1
Article Type:	Research
Date Submitted by the Author:	14-Mar-2018
Complete List of Authors:	Murley, Chantelle; Karolinska Institutet Department of Clinical Neuroscience, Division of Insurance Medicine; Karolinska Institutet, Department of Learning, Informatics, Management and Ethics Mogard, Olof; Karolinska Insitutet, Department of Learning, Informatics, Management and Ethics Wiberg, Michael; Karolinska Institutet Department of Clinical Neuroscience, Division of Insurance Medicine Alexanderson, Kristina; Karolinska Institutet Department of Clinical Neuroscience, Division of Insurance Medicine Karampampa, Korinna; Karolinska Insitutet, Department of Learning, Informatics, Management and Ethics Friberg, Emilie; Karolinska Institutet Department of Clinical Neuroscience, Division of Insurance Medicine Tinghög, Petter; Karolinska Institutet Department of Clinical Neuroscience, Division of Insurance Medicine
Primary Subject Heading :	Health economics
Secondary Subject Heading:	Occupational and environmental medicine, Public health
Keywords:	Multiple sclerosis < NEUROLOGY, Welfare state, Sick leave, Insurance benefits, Socioeconomic status, Income

SCHOLARONE[™] Manuscripts

Page 1 of 30

1

59

60

BMJ Open

2				
3	1	Title: Trajectories of disposable income among people of working ages diagnosed with multiple		
4 5	2	sclerosis: A nationwide register-based cohort study in Sweden 7 years before to 4 years after diagnosis		
6	3	with a population-based reference group		
7	U U			
8				
9	4	Authors and affiliations:		
10 11	5	Chantelle Murley ^{1,2} , Olof Mogard ² , Michael Wiberg ¹ , Kristina Alexanderson ¹ , Korinna		
12	6	Karampampa ^{2} , Emilie Friberg ^{1} , Petter Tinghög ^{$1,3$}		
13	Ū			
14	7	¹ Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, SE- 171 77 Stockholm, Sweden.		
15	8			
16 17	9	² Department of Lefermetics Management and Eddies Kenelinsky Instituted SE 171.77		
17		² Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.		
19	10	Stockholm, Sweden.		
20	11	³ Red Cross University College, SE-114 28 Stockholm, Sweden.		
21				
22 23	12	Corresponding author: Chantelle Murley		
23 24	13	Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska		
25	13	Institutet, SE-171 77 Stockholm, Sweden.		
26				
27	15	Phone: +46 76 0603003		
28	10	Form 146 (0) 8 524 822 05		
29 30	16	Fax: +46 (0)8 524 832 05		
31	17	chantelle.murley@ki.se,		
32				
33	18	chantelle.murley@ki.se, Abstract word count:297 Text word count:4668 Number of references:48		
34 35	19	Text word count:4668		
36				
37	20	Number of references:48		
38	21	Number of tables: 4		
39	21	Number of tables. 4		
40 41	22	Number of figures: 2		
42	20			
43	23	KEYWORDS: Multiple Sclerosis, Welfare state, Sick leave, Insurance benefits, Socioeconomic		
44	24	status, Income		
45				
46 47	25			
48	25			
49				
50				
51 52				
52 53				
55 54				
55				
56				
57				
58				

26 ABSTRACT:

Objectives: To describe how disposable income (DI) and three main components changed, and
analyse whether DI development differed from working-aged people with multiple sclerosis (MS) to a
reference group from 7 years before to 4 years after diagnosis in Sweden.

30 Design: Population-based cohort study, 12 years follow-up (seven years before to four years after
31 diagnosis).

32 Setting: Swedish working-age population with microdata linked from two nationwide registers.

33 Participants: Residents diagnosed with MS in 2009 aged 25-59 (n=785), and references without MS

34 (n=7847) randomly selected with stratified matching (sex; age; education; and country of birth).

Primary and secondary outcome measures: DI was defined as the annual after tax sum of incomes
(earnings and benefits), to measure individual economic welfare. Three main components of DI were
analysed as annual sums: earnings; sickness absence benefits; and disability pension benefits.

Results: We found no differences in mean annual DI between people with and without MS by independent t-tests (p-values between 0.15-0.96). Differences were found for all studied components of DI from diagnosis year by independent t-tests, for example in the final study year (2013): earnings (-64,867SEK; 95% CI:-79,203--50,528); sickness absence benefits (13,330SEK; 95% CI:10,042-16,500); and disability pension benefits (21,360SEK; 95% CI:17,380-25,350). A generalised estimating equation evaluated DI trajectory development between people with and without MS to find both trajectories developed in parallel, both before (-4039SEK; 95% CI:-10,536-2458), and after (-781SEK; 95% CI:-6988-5360) diagnosis.

46 Conclusions: The key finding of parallel DI trajectory development between working-aged MS and 47 references suggests minimal economic impact within the first four years diagnosis. The Swedish 48 welfare system was responsive to the observed reductions in earnings around MS diagnosis through 49 balancing DI with morbidity-related benefits. Future decreases in economic welfare may be 50 experienced as the disease progresses, although thorough investigation with future studies of modern 51 cohorts are required. Page 3 of 30

60

BMJ Open

1		
2	50	
3	52	
4 5		
5	53	
7		
	54	
8 9		
10	55	
11	55	
12		
13 14	56	
15		
16	57	ARTICLE SUMMARY:
17 18	58	Strengths and limitations
19	50	The main strength of this to be include hoth the menulation have design and use of mations with
20	59	• The main strengths of this study include both the population-based design and use of nationwide
21 22	60	registers with high completeness and validity, which enabled measurement of multiple sources of
23 24	61	income of a recently diagnosed MS cohort.
25 26	62	• The longitudinal study design with repeated measures enabled the study of the development of
27 28	63	disposable income for working-aged people with MS pre- and post-diagnosis, in addition to the
29 30	64	difference in annual levels of different income sources to a population-based reference group.
31 32	65	• While residual confounding cannot be excluded, the reference group was a randomised stratified
33 34	66	matched group from the general population at a ratio of 1:10.
35 36	67	• An important limitation is that this study does not address the long-term association between
37 38	68	economic welfare and MS, as the follow-up was only four years in the post-diagnosis period.
39		
40		
41		
42 43		
44		
45		
46		
47		
48		
49 50		
50		
52		
53		
54		
55		
56 57		
57		
59		

1. INTRODUCTION

Multiple sclerosis (MS) is the leading cause of non-traumatic neurological disability in younger adults.¹⁻⁴ People with MS (PwMS) in Sweden have a mean onset age of 33 for first symptoms, but experience a time-lag of 6-7 years before receiving a formal diagnosis with this chronic and progressive disease.⁵ Previous research has found MS to be associated with progressive work incapacity, due to physical disability worsening as time from onset increases.⁵⁻¹¹ Therefore, levels of absenteeism, with high proportions working part-time and exiting paid work, and presenteeism, with reduced work productivity, increase over the disease course.⁵ ⁹ However, there is uncertainty and variability among PwMS in progression to disability milestones.¹² The indirect costs of working-aged PwMS become a dominating cost as the disease progresses from a societal perspective.⁵ ¹³⁻¹⁵ Nonetheless, the impact of MS on the individual's economic welfare remains relatively unknown.

Earnings remain an important income source for PwMS.^{3 16} However, earnings alone provide an
incomplete picture of an individual's economic welfare; limited to describing the individual's labour
market participation and income generation.^{3 16} A recent Swedish survey found that 77% of PwMS
worked part-time, and participation in paid work rapidly decreased with advancing disease.⁵

The wider socioeconomic context can mediate the economic impact of MS on the individual.^{17 18} The Swedish welfare state aims to protect individuals with chronic disease from economic pressure through universal healthcare and social insurance benefits. The most substantial of these benefits for PwMS are the temporary sickness absence (SA) and permanent or long-term disability pension (DP) benefits; both designed to compensate a proportion of previous earnings reduced by morbidity-related absence.

90 There is a growing body of evidence of the positive associations between MS progression in terms of 91 physical disability and cognitive function with the morbidity-related benefits.¹⁹⁻²² Furthermore, a 92 substantially higher proportion of PwMS receive SA and DP, in comparison to the general 93 population.^{3 21 23} These changes in sources of income are observed to often occur within a few years of 94 symptom onset, indicating that morbidity-related benefits are necessary to consider when investigating

BMJ Open

95 the economic situation of working-aged PwMS.^{16 24-26} However, the collective impact of these changes 96 in incomes to the individual's economic welfare is largely unknown. Thorough investigation on how 97 MS affects the economic resources available to PwMS in Sweden necessitates the need to 98 longitudinally assess multiple sources of income in totality.^{3 21 23 27-30}

Disposable income (DI) is comprised of multiple income sources, enabling a comprehensive nuanced description of economic welfare that better reflects an individual's consumption potential than the individual income sources.^{3 31} DI is the "sum of factor income (income from work and capital) and net income from transfers (government benefits), minus income taxes, and fees paid to the government".¹⁶ Despite an increasing number of studies on PwMS receiving SA and DP benefits or about earnings, little is known about how MS impacts one's DI trajectory development in a welfare state.^{3 20 21} Longitudinal Danish studies have applied DI concepts by combining both earnings before tax and DP benefits, but not income from SA benefits, to suggest PwMS maintain similar trajectories while remaining in paid work.^{25 32} Nevertheless, the full magnitude of the current economic consequences for individuals with MS remains unknown in the Swedish welfare state where the context for MS has changed substantially in recent years due to treatments delaying disability progression and policy environments for SA and DP grants.33-35

111 This study aimed to describe the development of disposable income (DI) and three main components 112 (SA, DP, and earnings), among working-aged people diagnosed with MS in the years immediately 113 before and after diagnosis and compare with people without MS, in order to gain knowledge on the 114 economic welfare of working-aged people diagnosed with MS in a welfare state.

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

116 2. METHODS

2.1 Study design

We conducted a cohort study to measure the levels and development of mean annual DI and its main components (SA, DP, and earnings) among PwMS aged 25-59 at diagnosis in Sweden, in relation to matched references without MS. The index year of diagnosis, 2009, is presented as Y_0 , with the seven years of observation before and four years after diagnosis as Y_{-7} to Y_{-1} and Y_{+1} to Y_{+4} respectively.

122 2.2 Data sources

- 123 Person-level data were obtained from the following two nationwide Swedish registers:
- Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA),
 held by Statistics Sweden, was used to obtain sociodemographic variables and the sums of
 annual income from the different sources across follow-up.
- 127 2) *National Patient Registers*, held by the National Board of Health and Welfare, enabled
 128 identification of all people with an MS diagnosis. The registers contain healthcare visits for
 129 inpatient treatment by the International Classification (ICD) codes, ICD-9 (340) and 10 (G35)
 130 (1987-2009), and specialised outpatient treatment by ICD-10 (2001-2009).
 - 131 The linkage of data was performed using the unique personal identity numbers assigned to every132 resident in Sweden.

133 2.3 Study population

The study population was sourced from the total population registered as living in Sweden on 31 December 2009 (from LISA). The cohort of PwMS included all 785 PwMS identified with an incident MS diagnosis in 2009 and on 31 December 2009 aged 25-59 years. The age range allowed for the cohort to be of working ages in all studied years, with 65 years being the customary age for old-age pension in Sweden. All people with their first MS diagnosis according to the national patient registers

BMJ Open in 2009 were included, excluding all with a previous MS diagnosis (according to the in- and specialised out-patient registers).²³ We established a matched reference cohort of people who before 2010, according to the in- and specialised out-patient registers, were not diagnosed with MS. Among all without MS, who according to LISA, lived in Sweden 31 December 2009, we randomly selected ten references for each PwMS, matched on age, gender, educational level, and birth country in 2009 (Y_0). This produced a stratified matched reference group with the same distribution of the selected sociodemographic variables in Y_0 to the MS cohort. The 1:10 ratio of references could not be met for one individual with MS, with only seven possible references in the general Swedish population matching the particular combination of sociodemographic variables. In all, 7847 references were included at Y_0 . The maximum number of years of observation was 12, with 97.3% (n=764) of the PwMS and 97.8% (n=7671) of the reference group in the study at the end of follow-up (Y_{+4}) . Missing income data in LISA, due to migration before/after the index year or death after Y₀, led to small proportions of individuals across both groups not being followed for the entirety of follow-up. 2.4 Patient and Public Involvement This was a study based on national register data and there was no patient or public involvement. 2.5 Variables Our main outcome measure was annual disposable income (DI). We used the DI measure constructed by Statistics Sweden, contained in LISA. This was the sum of incomes after tax, with sources

including: income from work and public benefits such as disability pension; sickness absence;
disability allowance; unemployment compensation; old-age pension; and social assistance.³⁶ DI was
an individualised measure of household DI, calculated as the sum of household incomes, adjusted for
household size and the individual's consumption weight to produce a continuous variable.³⁶

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

162 The three main components of DI for working-aged PwMS were also included as secondary economic163 outcomes in analyses as the mean annual sum:

Sickness absence (SA): All people living in Sweden above the age of 16 are covered by public sick-leave insurance if they receive income from work or unemployment benefits and, if due to disease or injury, have work incapacity. The Social Insurance Agency pays the granted sickness absence benefits, of up to 80% of lost earnings, at 100, 75, 50 or 25% of ordinary working hours. Among employees, the employer provides sick pay the first 13 days of a sick-leave spell after the first uncompensated day;

Disability pension (DP): All residents aged 19-64 can be granted disability pension if disease
 or injury leads to long-term or permanent work incapacity. Benefits of up to 64% of the lost
 earnings are paid by the Social Insurance Agency, at 100, 75, 50 or 25% of ordinary working
 hours; and

• Earnings: Income from work was in the form of gross earnings (before tax deductions). This included the sick pay provided by the employer during the first 14 days of a sick-leave spell.

Earnings were presented in gross form and only two potential public benefit payments were included in the analyses, therefore, one cannot sum the three components to the presented DI values. All monetary values were presented in Swedish Krona (SEK) and adjusted for inflation by the Statistics Sweden Harmonised Consumer Price Index (HCPI) by the annual average 2016 value.³⁷

180 The following sociodemographic variables, sourced from LISA, were included in the analyses as181 explanatory variables:

- Age (continuous, time variant): In addition, age was also computed into a new continuous variable to control for curvilinearity in the statistical analyses by squaring the values for age;
- Gender (binary);

185	• Educational level (categorical, time variant: elementary; high school; college or university;
186	and missing); and
187	• Birth country (categorical: Sweden; Other Nordic Countries; Other EU25 Countries; Rest of
188	World; and missing).
189	The study cohort had near complete data with less than 0.25% missing values for country of birth, and
190	0.5% for educational level.
191	2.6 Ethical approval
192	The project was approved by the Regional Ethical Review Board of Stockholm, Sweden.
193	2.7 Statistical analyses
194	Data management and statistical analyses were conducted in SAS v.9.4, with the exception of
195	generalised estimating equation (GEE) models, which were calculated in SPSS v.24.
100	
196	In our data management, we set 337 negative DI values between 2004 and 2013 to zero to prevent
197	distortion of the DI means over time. This was required as Statistics Sweden changed how they coded
198	DI in LISA; earlier years of follow-up had a lower limit of zero, but negative values were possible
199	from 2004. We trimmed extreme outlier DI values at 566,100 SEK, representing the 99th percentile of
200	annual DI across all study years. This made the distribution of DI reasonably normal for statistical
201	analyses. Individuals with missing values in LISA for DI and the secondary outcomes, in years other
202	than Y_{0} , were excluded in descriptive statistics for the respective years, but were included in the GEE
203	model. Earnings were also capped at the 99 th percentile (810,400 SEK) to control for extreme outliers.
204	Descriptive statistics were performed to describe the distribution of sociodemographic variables and
205	summarise the levels of the different incomes. Categorical data were expressed as frequency
206	distributions with the number and percentage. Continuous data were reported for both the PwMS and
207	the reference group, expressed by the mean, 95% confidence intervals (95% CI), and both the number
208	and proportion with annual sums >0 . ³⁸

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

The means of annual DI of PwMS was calculated for each year, $Y_{.7}$ to Y_{+4} . The differences in mean annual DI of PwMS were tested for statistical significance by dependent t-tests between the following three time points: $Y_{.7}$ to Y_0 ; Y_0 to Y_{+4} ; and $Y_{.7}$ to Y_{+4} . Independent two-tailed t-tests with Satterthwaite approximation for unequal variance were performed for each year of follow-up to test the difference in mean annual DI between PwMS and the references. The mean differences in annual sums of earnings, SA benefits, and DP benefits between PwMS and references were calculated with 95% CI at three time points: $Y_{.7}$; Y_0 ; and Y_{+4} .

Lastly, we conducted linear regression analyses, using the generalised estimating equation (GEE) method to analyse how MS influenced the DI trajectory development over the study period.³⁹ The GEE model described the difference in the slopes of the DI trajectories from $Y_{.7}$ to Y_{+4} between PwMS and the reference group. The method allowed for the dependent repeated measures of DI by accounting for the clustering of observations at both the individual and group levels that violated independence assumptions.³⁹⁻⁴¹ The dependent variable, DI, was analysed as a continuous measure. The DI distribution was slightly right skewed, but GEE is a robust method.⁴⁰ The GEE model was computed with the following specifications: a normal distribution; identity link; and autoregressive within-subject correlation. The within-subject correlation structure was selected because of the reasonable assumption that the correlation between an individual's annual DI values diminished over time. The models were adjusted for gender, age, education level, and country of birth. An additional age variable was included to account for curvilinearity. All variables were entered simultaneously with an interaction term of MS and year to evaluate whether PwMS had a different DI trajectory than the references. The periods pre- and post-diagnosis were assessed in separate models. The GEE model results were presented as un-standardised Beta regression coefficients with 95% CI, which can be interpreted as values in SEK. The significance level for all analyses was $\alpha = 0.05$.

BMJ Open

RESULTS

We observed growth of annual DI experienced by both the PwMS and the reference group over the study period. There were significant differences between PwMS and the reference group in mean annual sums of SA benefits, DP benefits, and earnings along the disease trajectory. No differences in either the levels or development of mean annual DI between $Y_{.7}$ and Y_{+4} were observed.

Table 1 contains a basic description of the study population and shows that the reference group (n= 7847) was representative of the PwMS cohort (n=785) on the distribution of these sociodemographic variables. The MS cohort had a mean age of 41 (95% CI: 40.7-42.0) in Y₀, and a female to male ratio of 2.17. BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

1 2 3	242	Table 1: Sociodemographic characteristic	s of the study	population a	t year of di	agnosis (2009)
4 5				MS ^b	Ref	erences ^b
6			n	(%)	n	(%)
7			785	(100)	7847	(100)
8		Sex Women	537	(68.4)	5367	(68.4) ^a
9		Men	248	(31.6)	2480	$(31.6)^{a}$
10		Age Group				
11 12		25-34 35-44	213 279	(27.1) (35.5)	2130 2790	(27.1) ^a (35.6) ^a
12		45-54	208	(26.5)	2077	$(26.5)^{a}$
13 14		55-59	85	(10.8)	850	(10.8) ^a
14		Education (in years)		(1.4.1)	1107	(1 4 1) 8
15		≤9 (elementary) ^c 10 -12 (high school)	111 355	(14.1) (45.2)	1107 3550	(14.1) ^a (45.2) ^a
10		>12 (college or university)	319	(40.6)	3190	$(40.7)^{a}$
18		Country of Birth				
19		Sweden	677	(86.2)	6770	$(86.3)^{a}$
20		Nordic countries (except Sweden) EU25 (except Nordics)	23 27	(2.9)	230 270	$(2.9)^{a}$ (3.4) ^a
20 21		Rest of the world ^c	58	(3.4) (7.4)	270 577	$(3.4)^{a}$ (7.4) (7.4)
21		^a Reference group matched to MS cohort	t on these vari	ables.		<u> </u>
23		^b MS: Multiple sclerosis (MS) diagnosis	first registere	d in 2009 in 1	nationwide	in- and
24		specialised out-patient registers. Referen			listribution	$(1 \rightarrow 10)$
25		with no registered MS diagnosis in years ^c Individuals with missing variables adde			% of both	study
26						study
20						
28	243					
20						
30	244					
31						
32						
33						
34						
35						
36						
37						
38						
39						
40						
41						
42						
43						
44						
45						
46						
47						
48						
49						
50						
51						
52						
53						
54						
55						
56						
57						
58						
58 59						
60		For peer review only - http://bmjc	pen.bmi.co	om/site/ab	out/quid	elines.xhtml
00			,		5	

BMJ Open

In Y₀, PwMS had a mean annual DI of 177,040 SEK (95% CI: 170,170-183,920) (Figure 1). PwMS experienced a mean increase in annual DI over the 12-year study period of 51,400 SEK (95% CI: 43,330-59,510). This increase in mean annual DI was observed in both the periods before (32,360 SEK; 95% CI: 26,360-38,360) and after diagnosis (19,390 SEK; 95% CI: 12,760-26,010) by dependent t-tests.

250 (INSERT FIGURE ONE)

To further investigate the mean annual DI of PwMS, comparison was made to the reference group. **Figure 2** suggests there were differences in mean annual DI between PwMS and the reference group, where the reference group consistently had higher annual DI means, from four years prior to MS diagnosis. This suggested gap widened over time. However, independent t-tests suggested that these differences were statistically non-significant (p-values ranged between 0.15-0.96) (not presented).

256 (INSERT FIGURE TWO)

Table 2 displays the differences in the mean annual sums of the main components of DI (earnings, SA benefits, and DP benefits) between PwMS and references in Y₋₇, Y₀, and Y₊₄. In every year, both SA and DP had a median of zero; indicating that most individuals in both groups did not receive either benefit (not presented). A trend for PwMS to have greater sums of income from morbidity-related benefits than the references was present from Y₋₇ (DP mean difference: 5571 SEK; 95% CI: 1773-9369). The proportion of PwMS who received each of the benefits, SA and DP, increased over time. However, substantial skewedness of income from these morbidity-related sources remained even among PwMS; in each year less than 30% of PwMS had annual income from each benefit (except SA in Y₀, 44%). This skewness was larger among the references (<17 %). Notwithstanding, in every year studied, the mean SA and DP amounts were higher for PwMS than for the reference group with differences in all years, apart from SA benefits in 2002 (Y_{-7}). PwMS had a peak in SA in Y_0 with the DP benefits increasing in the post-diagnosis period, whereas the references had stable DP sums and proportions across follow-up. From the time of diagnosis Y₀, PwMS had significantly lower earnings than the reference group, with this trend continuing throughout the post-diagnosis period.

Mean sum *95% CInd9/2dMean sum *95% CInd 26^{d} $Y_{1,5}^{*}$ 74774774577457Sickness absence10,829(8369-12,293)147208523(7804-9243)1289172306(-257-4868)Disability pension13,966(10,281-17,654)6388396(7460-9312)38355571(1773-9369)Earnings *184,174(172,691-195,658)64586193,918(190,357-197,467)665389-9742(-21,763-2275)Disposable income * f149,060(144,180-153,940)150,110(148,530-151,700)1051(-6184-4073)Disposable income * f10,866-16,230103138571(7871-9270)62984977(2208-7745)Disability pension13,548(10,866-16,230)103138571(7871-9270)629849771(2208-7745)Disposable income * f177,040(170,170-183,920)182,010(179,750-184,280)49711(-12,210-2266)Vi_4 *5629,63(564-6862)9631313,330(10,042-16,500)00287908(722-83,534)671988-64,867(-79,203-50,528)Disposable income * f19,350(19,540-207,160)205,450(202,950-207,950)4971(-12,210-226,5		<u>MS ^c</u>				<u>References ^c</u>			Mean difference	95%CI	
Sickness absence 10,829 (8369-12,293) 147 20 8523 (7804-9243) 1289 17 2306 (-257-4868) Disability pension 13,966 (10,281-17,654) 63 8 8396 (7480-9312) 383 5 5571 (1773-9369) Earnings ^b 184,174 (172,691-195,658) 645 86 193,918 (190,357-197,467) 6653 89 -9742 (-21,763-2275) Disposable income ^{b.f} 149,060 (144,180-153,940) 150,110 (148,530-151,700)1051 (-6184-4073) Y ₀ ^e 785 7847 Sickness absence 26,685 (23,178-30,179) 347 44 3995 (3549-4442) 811 10 22,693 (19,155-26,220) Disposable income ^{b.f} 207,834 (195,427-20,242) 651 83 248,352 (244,339-252,365) 6791 87 -40,517 (-53,558-27,476) Disposable income ^{b.f} 177,040 (170,170-183,920) 182,010 (179,750-184,280) 4971 (-12,210-2266) Y _{4.4} ^e 7671 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disability pension 29,269 (25340-33,199) 210 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Earnings ^b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203-50,528) Disposable income ^{b.f} 19,597 (16,363-22,819) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203-50,528) Disposable income ^{b.f} 19,350 (191,540-207,160) 205,450 (202,950-207,950) 6098 (-14,300-2103) Trimmed at the 99 percentile. ^{b.f} Trimmed at the 99 percentile.		Mean sum ^a	<u>95% CI</u>	\underline{n}^{d}	<u>%</u> d	Mean sum ^a	<u>95% CI</u>	\underline{n}^{d}	<u>%</u>		
Sickness absence 10,829 (8369-12,293) 147 20 8523 (7804-9243) 1289 17 2306 (-257-4868) Disability pension 13,966 (10,281-17,654) 63 8 8396 (7480-9312) 383 5 5571 (1773-9369) Earnings ^b 184,174 (172,691-195,658) 645 86 193,918 (190,357-197,467) 6653 89 -9742 (-21,763-2275) Disposable income ^{b r} 149,060 (144,180-153,940) 150,110 (148,530-151,700)1051 (-6184-4073) Y ₀ ^c 785 7847 Sickness absence 26,685 (23,178-30,179) 347 44 3995 (3549-4442) 811 10 22,693 (19,155-26,220) Disposable income ^{b r} 13,548 (10,866-16,230) 103 13 8571 (7871-9270) 629 8 4977 (2208-7745) Earnings ^b 207,834 (195,427-220,242) 651 83 248,552 (244,339-252,365) 6791 87 -40,517 (-53,558-27,476) Disposable income ^{b r} 177,040 (170,170-183,920) 182,010 (179,750-184,280) 4971 (-12,210-2266) Y ₄ ^c 764 7671 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disability pension 29,269 (25340-33,199) 210 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Earnings ^b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203-50,528) Disposable income ^{b r} 199,350 (191,540-207,160) - 205,450 (202,950-207,950) 6098 (-14,300-2103) ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK ≈ 10.5 Euros. ^b Trimmed at the 99 percentile. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1→10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^e Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.	X 7 6										
Disability pension 13,966 (10,281-17,654) 63 8 8396 (7480-9312) 383 5 5571 (1773-9369) Earnings ^b 184,174 (172,691-195,658) 645 86 193,918 (190,357-197,467) 6653 89 -9742 (-21,763-2275) Disposable income ^{b f} 149,060 (144,180-153,940) 150,110 (148,530-151,700)1051 (-6184-4073) Y ₀ ^e 785 7847 Sickness absence 26,685 (23,178-30,179) 347 44 3995 (3549-4442) 811 10 22,693 (19,155-26,220) Disability pension 13,548 (10,866-16,230) 103 13 8571 (7871-9270) 629 8 4977 (2208-7745) Earnings ^b 207,834 (195,427-220,242) 651 83 248,352 (244,339-252,365) 6791 87 -40,517 (-53,558-27,476) Disposable income ^{b f} 177,040 (170,170-183,920) 182,010 (179,750-184,280) 49711 (-12,210-2266) Y ₊₄ ^e 764 7671 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disposable income ^{b f} 199,350 (191,540-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disposable income ^{b f} 199,350 (191,540-207,160) - 205,450 (202,950-283,534) 6719 88 -64,867 (-79,203-50,528) Disposable income ^{b f} 199,350 (191,540-207,160) - 205,450 (202,950-207,950) 6098 (-14,300-2103) ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK ≈ 10.5 Euros. ^b Trimmed at the 99 percentile. ^b Mis: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1→10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^c Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.		10.000	(92(0, 12, 202)		20	0.500	(7804 0242)		17	2200	(257 49(9)
Earnings ^b : 184,174 (172,691-195,658) 645 86 193,918 (190,357-197,467) 6653 89 -9742 (-21,763-2275) Disposable income ^{b f} 149,060 (144,180-153,940) 150,110 (148,530-151,700)1051 (-6184-4073) Y ₀ * 785 7847 Sickness absence 26,685 (23,178-30,179) 347 44 3995 (3549-4442) 811 10 22,693 (19,155-26,220) Disposable income ^{b f} 177,040 (10,867-16,200) 103 13 8571 (7871-9270) 629 8 4977 (2208-7745) Earnings ^b 207,834 (195,427-220,242) 651 83 248,352 (244,339-252,365) 6791 87 -40,517 (-53,5587,746) Disposable income ^{b f} 177,040 (170,170-183,920) 182,010 (179,750-184,280) 4971 (-12,210-2266) Y ₊₄ [€] 7671 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disposable income ^{b f} 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disposable income ^{b f} 19,597 (16,363-22,831) 92 10 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Earnings ^b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,20350,528) Disposable income ^{b f} 199,350 (191,540-207,160) - 205,450 (202,950-207,950) - 6098 (-14,300-2103) ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK ≈ 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1→10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^c Y-7 = 2002, YO = 2009 and Y+4 = 2013.											
Disposable income ^{b.f} 149,060 (144,180-153,940) 150,110 (148,530-151,700)1051 (-6184-4073) Y ₀ ^c 785 7847 Sickness absence 26,685 (23,178-30,179) 347 44 3995 (3549-4442) 811 10 22,693 (19,155-26,220) Disability pension 13,548 (10,866-16,230) 103 13 8571 (7871-9270) 629 8 4977 (2208-7745) Earnings ^b 207,834 (195,427-220,242) 651 83 248,352 (244,339-252,365) 6791 87 -40,517 (-53,558 - 27,476) Disposable income ^{b.f} 177,040 (170,170-183,920) 182,010 (179,750-184,280) 4971 (-12,210-2266) Y ₊₄ ^c 764 7671 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disability pension 29,269 (25340-33,199) 210 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Disposable income ^{b.f} 199,350 (191,540-207,160) - 205,450 (202,950-207,950) 6098 (-14,300-2103) ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK ≈ 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1→10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^c Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.	Disability pension										
Y ₀ ° 785 7847 Sickness absence 26,685 (23,178-30,179) 347 44 3995 (3549-4442) 811 10 22,693 (19,155-26,220) Disability pension 13,548 (10,866-16,230) 103 13 8571 (7871-9270) 629 8 4977 (2208-7745) Earnings b 207,834 (195,427-220,242) 651 83 248,352 (244,339-252,365) 6791 87 -40,517 (-53,558-27,476) Disposable income b f 177,040 (170,170-183,920) - - 182,010 (179,750-184,280) - - -4971 (-12,210-2266) Y ₄ 4 764 761 764 7671 71 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) 17,380-25,350) Earnings b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203-50,528) Disposable income b f 199,350 (191,540-207,160) - </td <td>Earnings</td> <td></td>	Earnings										
Sickness absence 26,685 (23,178-30,179) 347 44 3995 (3549-4442) 811 10 22,693 (19,155-26,220) Disability pension 13,548 (10,866-16,230) 103 13 8571 (7871-9270) 629 8 4977 (2208-7745) Earnings b 207,834 (195,427-220,242) 651 83 248,352 (244,339-252,365) 6791 87 -40,517 (-53,558 - 27,476) Disposable income b f 177,040 (170,170-183,920) 182,010 (179,750-184,280) 4971 (-12,210-2266) Y_{+4}^{c} 764 7671 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disability pension 29,269 (25340-33,199) 210 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Earnings b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203 - 50,528) Disposable income ^{b f} 199,350 (191,540-207,160) - 205,450 (202,950-207,950) 6098 (-14,300-2103) ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK ≈ 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1→10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^c Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.	Disposable income	149,060	(144,180-153,940)		-	150,110	(148,530-151,700)	-	-	-1051	(-6184-40/3)
Sickness absence 26,685 (23,178-30,179) 347 44 3995 (3549-4442) 811 10 22,693 (19,155-26,220) Disability pension 13,548 (10,866-16,230) 103 13 8571 (7871-9270) 629 8 4977 (2208-7745) Earnings ^b 207,834 (195,427-220,242) 651 83 248,352 (244,339-252,365) 6791 87 -40,517 (-53,558 - 27,476) Disposable income ^{b f} 177,040 (170,170-183,920) 182,010 (179,750-184,280)4971 (-12,210-2266) Y ₄ . ^e 764 7671 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disposable income ^{b f} 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203 - 50,528) Disposable income ^{b f} 199,350 (191,540-207,160) 205,450 (202,950-207,950) 6098 (-14,300-2103) ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK \approx 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1 \rightarrow 10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^e Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.	Y ₀ ^e			785				7847			
Disability pension 13,548 (10,866-16,230) 103 13 8571 (7871-9270) 629 8 4977 (2208-7745) Earnings ^b 207,834 (195,427-220,242) 651 83 248,352 (244,339-252,365) 6791 87 -40,517 (-53,558 - 27,476) Disposable income ^{b f} 177,040 (170,170-183,920) 182,010 (179,750-184,280) 4971 (-12,210-2266) Y_{+4}^{e} 764 7671 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disability pension 29,269 (25340-33,199) 210 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Earnings ^b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203 - 50,528) Disposable income ^{b f} 199,350 (191,540-207,160) - 205,450 (202,950-207,950) 6098 (-14,300-2103) ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK ≈ 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1→10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^c Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.	Sickness absence	26,685	(23,178-30,179)		44	3995	(3549-4442)		10	22,693	(19,155-26,220)
Earnings ^b 207,834 (195,427-220,242) 651 83 248,352 (244,339-252,365) 6791 87 -40,517 (-53,55827,476) Disposable income ^{b f} 177,040 (170,170-183,920) 182,010 (179,750-184,280) 4971 (-12,210-2266) Y_{+4}^{c} 764 7671 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disability pension 29,269 (25340-33,199) 210 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Earnings ^b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203 - 50,528) Disposable income ^{b f} 199,350 (191,540-207,160) 205,450 (202,950-207,950) 6098 (-14,300-2103) ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK ≈ 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1 \rightarrow 10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^e Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.											
Disposable income ^{b.f} 177,040 (170,170-183,920) 182,010 (179,750-184,280)4971 (-12,210-2266) Y_{+4}^{e} 764 7671 Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disability pension 29,269 (25340-33,199) 210 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Earnings ^b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203 - 50,528) Disposable income ^{b.f} 199,350 (191,540-207,160) 205,450 (202,950-207,950)6098 (-14,300-2103) ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK ≈ 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1→10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^e Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.	Earnings ^b										
Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disability pension 29,269 (25340-33,199) 210 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Earnings ^b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203 - 50,528) Disposable income ^{b f} 199,350 (191,540-207,160) 205,450 (202,950-207,950) 6098 (-14,300-2103) a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK \approx 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1 \rightarrow 10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^e Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.	Disposable income ^{b f}										
Sickness absence 19,597 (16,363-22,831) 220 29 6263 (5664-6862) 963 13 13,330 (10,042-16,500) Disability pension 29,269 (25340-33,199) 210 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Earnings ^b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203 - 50,528) Disposable income ^{b f} 199,350 (191,540-207,160) 205,450 (202,950-207,950) 6098 (-14,300-2103) a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK \approx 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1 \rightarrow 10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^e Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.	V. ^e			764				7671			
Disability pension 29,269 (25340-33,199) 210 28 7908 (7226-8590) 558 7 21,360 (17,380-25,350) Earnings ^b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,203 - 50,528) Disposable income ^{b f} 199,350 (191,540-207,160) 205,450 (202,950-207,950)		19 597	(16 363-22 831)		29	6263	(5664-6862)		13	13 330	(10.042 - 16.500)
Earnings ^b 214,426 (200,723-228,119) 582 76 279,298 (275,050-283,534) 6719 88 -64,867 (-79,20350,528) Disposable income ^{bf} 199,350 (191,540-207,160) 205,450 (202,950-207,950)											
Disposable income ^{b f} 199,350 (191,540-207,160) 205,450 (202,950-207,950)6098 (-14,300-2103) ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK \approx 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1 \rightarrow 10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^e Y-7 = 2002, Y0 = 2009 and Y+4 = 2013.	Earnings ^b										
 ^a Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK ≈ 10.5 Euros. ^b Trimmed at the 99 percentile. ^c MS: Multiple sclerosis (MS) diagnosis first registered in 2009 in national in- and specialised out-patient registers. References: matched on variable distribution (1→10) with no registered MS diagnosis in years before 2010. ^d Number count or proportion receiving annual sums > 0. ^e Y-7 = 2002, Y0 = 2009 and Y+4 = 2013. 	Disposable income ^{b f}										
^f Disposable income is the sum of incomes from earnings and benefits (in addition to SA and DP presented) after tax (net). Earnings are presented as gross (amount paid before taxable	registered MS diagnosi ^d Number count or prop ^e Y-7 = 2002, Y0 = 200	s in years before portion receiving 9 and $Y+4 = 20$	e 2010. g annual sums > 0. 013.			-					

reference group.

Potential differences in the development of the mean annual DI trajectory of PwMS from that of the matched references were assessed with a GEE model. In Figure 2, there were indications of the slopes both diverging prior to diagnosis and realigning to develop more in parallel in the years after diagnosis. All results from the GEE model provided non-significant differences between the development of the DI trajectories of PwMS and the reference group. Table 3 contains the differences in DI development after diagnosis in relation to the year of diagnosis, and shows that between Y₀ and $Y_{\rm +4}$ was on an average 781 SEK (95% CI: -6922-5360) less for PwMS than for the reference group. Analysis of the pre-diagnosis period is contained in Table 4, where from Y₋₇ to Y₀ the development of WMS was . mean annual DI for PwMS was on an average 4039 SEK (95% CI:-10,536-2458) lower than the

of people with MS

283 284 285 286	Table 3: Disposable Income (DI) trajectory post-diagnosis from Y_0 (2009) to Y_{+4} (2013) in the cohort of (N=785) compared to the cohort of references (N=7847) ^{a b}

	adjusted regression		
Year	coefficient ^{c d}	95% CI	
Y ₊₄ (2013)	-781	-6922-5360	
Y ₊₃ (2012)	1623	-3839-7085	
Y ₊₂ (2011)	1200	-4120-6520	
Y ₊₁ (2010)	1710	-3226-6646	

^a Reference groups for analysis: 2009 (Y_0) and reference group.

^b MS: Multiple sclerosis (MS) diagnosis first registered in 2009 (Y₀), in

national in- and specialised out-patient registers, n=785 in 2009. References: matched on variable distribution $(1\rightarrow 10)$ with no registered MS diagnosis in

years before and including 2009, n=7847 in 2009.

^c Adjusted for age, gender, education level and country of birth.

^d Un-standardised beta. Inflated to 2016 Swedish Krona (SEK) values by the

Harmonised Consumer Price Index. In 2017, 100 SEK \approx 10.5 Euros.

Table 4: Disposable Income (DI) trajectory pre-diagnosis from $Y_{.7}$ (2002) to Y_0 (2009) in the cohort of people with MS (N=785) compared to the cohort of references (N=7847) ^{a b}

Year	adjusted regression coefficient ^{cd}	95% CI
Y ₀ (2009)	-4039	-10,536-2458
Y ₋₁ (2008)	304	-6135-6742
Y- ₂ (2007)	-715	-6883-5454
Y ₋₃ (2006)	-2060	-7588-3468
Y ₋₄ (2005)	-863	-6085-4358
Y ₋₅ (2004)	258	-4681-5197
Y ₋₆ (2003)	-1515	-4844-1813

^a Reference groups for analysis: 2002 (Y₋₇) and reference group. ^b MS: Multiple sclerosis (MS) diagnosis first registered in 2009 (Y₀), in national in- and specialised out-patient registers n=785 in 2009. References: matched on variable distribution (1 \rightarrow 10) with no registered MS diagnosis in years before 2010, n=7847 in 2009.

^c Adjusted for age, gender, education level and country of birth.

^d Un-standardised beta. Inflated to 2016 Swedish Krona (SEK) values by the Harmonised Consumer Price Index. In 2017, 100 SEK \approx 10.5 Euros.

293 4. DISCUSSION

294 4.1 Principal findings

We have presented the mean DI development for working-aged PwMS from seven years before to four years after diagnosis, in comparison to a population-based stratified matched reference group without MS. Our principal finding was that within the first four years after diagnosis there was little change to PwMS' DI trajectory in comparison to those without MS. Both groups experienced parallel trajectory development despite substantial differences in the individual component sources of income: earnings; SA benefits; and DP benefits. Changes in morbidity-related benefits balanced the expected gap from reduced earnings to maintain the economic welfare of PwMS over follow-up. The result that both DI levels and development are similar can be interpreted as responsiveness of the Swedish welfare system to the potential economic consequences of work incapacity through benefit payments in the first years after MS diagnosis.

305 4.2 Interpretation of findings

306 Our interpretations are contextualized within the short-term, with observation pertaining to the years 307 early in the disease course. This is of importance in the context of a heterogeneous and progressive 308 disease, where baseline disability and age at onset are predictive of progression to milestones of 309 irreversible physical disability.^{35 42}

To situate our findings of DI, a Danish study found differences in the levels of mean annual gross income (pre-tax sums of earnings and benefit payments, but excluding SA benefits) only after 20years post-diagnosis, where PwMS received 70% of the mean annual gross income of matched references.²⁵ The difference was attributed to DP benefits (compensated as a proportion of previous earnings) becoming the largest source of income for PwMS by the end of this longer follow-up which allowed for increasing severity of disability and consequent morbidity-related absence from work.²⁵ Notable differences exist between the Danish and Swedish social security systems and labour markets.43 However, is likely that PwMS in Sweden would also experience reduced DI after a

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

substantially longer follow-up allowing for further disease progression, as long-term DP benefits compensate lost earnings to a lower proportion than short-term SA benefits.^{10 25} Earnings remained the main income source for our MS cohort, where 76% cohort still participated in paid work to some degree at the end of follow-up, reflecting findings of Wiberg et al. that notwithstanding changes in sources of income around diagnosis, earnings remain the dominant source.³ Furthermore, Hilt Pfleger et al. concluded that PwMS maintained similar levels of gross income to the references while remaining in paid work.²⁵ The combination of which supports our findings of similar DI trajectories between PwMS and the references in the short-term.

Despite the importance of earnings for maintaining economic welfare of working-aged PwMS, reductions in comparison to references were observed to begin early in the disease course. Similarly to Wiberg et al., we found that PwMS had lower mean annual earnings than the references from diagnosis, with the mean difference increasing with time from diagnosis.³ This trend of early and increasing heterogeneity of PwMS' earnings has been postulated to be due to the disparate levels of work incapacity, influenced by severity of physical disability and cognitive function independently, and variations in flexibility of occupations and workplaces to adapt.^{14 20 30 44-46} Furthermore, the level of earnings may be reduced of those who remain economically active due to truncated careers and underemployment.⁹ The accumulation of irreversible physical disability of MS is highly variable and related to both age of clinical onset and current age.⁴² As the disease progresses, future unbalanced changes in the component sources of DI may therefore occur through further reduced earnings due to increasing levels of work incapacity.592547

In line with previous research, we identified a larger proportion of PwMS receiving income from morbidity-related benefits than references, and PwMS transitioning from SA to DP benefits.^{3 10 47} These patterns were not found for the reference group; the proportions of references receiving SA benefits were larger than DP for all years. Nevertheless, most PwMS were observed to not be on either benefit within our study period, further suggesting that early stages of MS morbidity were observed. These morbidity-related benefits have an increasing role in consideration of the progressive nature of MS.^{10 20} SA benefits are designed to compensate periods of temporary absence from work, and

BMJ Open

following the progressive chronic characteristics of MS, permanent DP can be expected to increase with time.^{3 13 21 47} Consistent with the trends we observed, the literature suggests that while SA is highest among PwMS around diagnosis years, DP grants continue to increase with time.^{10 47} We observed DP surpassing SA benefits post-diagnosis. This increase of DP benefits can accordingly be expected to continue with time.^{10 22 47} Such a continuation would plausibly reduce future DI development due to the lower reimbursement by DP compared to SA benefits. Furthermore, previous research in Sweden, non-specific on diagnosis, suggested an association between SA benefits and lower subsequent DI levels.¹⁶

353 4.3 Strengths and limitations

A distinctive characteristic of this explorative study that adds to its strength and external validity was the use of nationwide registers. The registers provided the most complete data available and enabled both full inclusion of incident cases, and use of DI which could capture the complexity of incomes available to PwMS in Sweden including part-time SA and DP grants alongside earnings. Such complex combinations are important to acknowledge, especially with the early focus of our observation period.¹⁰ Our study reflects common methodological characteristics of register-based income studies of PwMS. MS status was ascertained by formal diagnosis by ICD codes. Despite the possibility for miscoding, this method was more objective than the alternative, onset of symptoms, which suffer inaccuracies from recall bias and attribution to MS.^{47 48} The longitudinal design included both pre- and post-diagnosis periods, to observe earlier progressive aspects of MS prior to diagnosis, such as relapses and resultant changes in income sources.⁴

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

An important limitation of our analyses and interpretations of economic welfare is the short-term perspective. Data was available up to 31 December 2013. The diagnosis year 2009 was selected to balance considerations of follow-up length (both before and after diagnosis), and to have a cohort reflecting current treatments and policy environments, especially regarding stricter requirements for SA and DP grants.^{33 34} Further, short SA spells (<14 days) were missing and the SA analyses may therefore be underestimated. However, the DI analyses were unaffected, as short spells were included

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright

within the composite indicator under earnings, because such spells are usually employer compensated except for the first uncompensated day. Our analyses assumed homogeneity within PwMS and did not consider the variation within the cohort by either sociodemographic or disease characteristics. We did not differentiate between the different grades of SA or DP benefits which are a unique feature of the Swedish social insurance system. The cohort being early in the disease course and with high proportions still engaged in paid work, such benefits were likely to be part-time for many in the cohort ^{20 22 30}. An additional assumption in our interpretation of economic welfare was that DI was distributed evenly within households according to need, but the actual distribution was unknown.^{28 31} Further, informal support by increased earnings of household members was also plausible.

380 4.5 Implications for policy and research

Our results reflect the combination of a responsive welfare system and the incremental progression of MS morbidity. The finding of unchanged levels and development of economic welfare, as measured by DI, in the presence of MS suggests that the morbidity-related transfer payments buffered the economic consequences of MS of reduced earnings in the years directly after diagnosis.²⁹ Our results suggest that society is bearing much of the economic burden associated with MS, which the individual would otherwise experience. The observation that the economic situation does not seem to differ much between the groups implies that that the flexible system of morbidity-related benefits that differentiate morbidity situations and levels of work incapacity in allowing part-time grants is necessary for PwMS to maintain similar levels of economic welfare to the general population early in the disease trajectory.

Moreover, current focus of MS treatment is on early intervention to delay disease progression, which should further preserve work capacity for longer periods post-diagnosis.^{14 22 35 48} These delaying effects of early initiated treatments have been found to extend to socioeconomic outcomes and reduce the risk of full-time DP, which in light of the lower compensation for DP benefits, could provide further protections of economic welfare.²²

Future research is required; we did not have the opportunity to capture long-term DI changes that mayoccur with further disease progression and increasing work incapacity. Lastly, we did not consider

BMJ Open

397 PwMS older than 65, who may experience different DI development to our study cohort as a
398 consequence of different income sources and benefit entitlements. This would be of particular interest
399 in the Swedish context where the prevalent MS population is comparatively older than in other
400 European countries.⁵ Our interpretations for working-aged persons with MS focused on the role of DP
401 benefits, which are not available for older adults.

402 5. CONCLUSIONS

Our results indicate that working-aged PwMS as a group have similar DI growth to those without MS in Sweden around time of diagnosis, and suggests that the potential economic impact of MS for the individual may arise later in the disease course. We found significant differences between PwMS and the population-based reference group in the individual income sources over the 12 year follow-up within both the pre- and post-diagnosis periods. However, no differences were found in the levels or development of the composite measure, annual DI, at least within the first four years post-diagnosis. In line with its intentions, the welfare system appears to be responsive to the individuals' economic welfare early in the disease course through balancing PwMS' DI, reflected in the reduced annual earnings balanced by increased SA and DP benefits.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

413 Figure Legends

- Figure 1: Mean disposable income (DI) $Y_{.7}$ to Y_{+4} among people diagnosed with multiple sclerosis (MS) in Y_0
- *Notes:* Mean annual DI with 95% confidence intervals illustrated. DI sums are inflated to 2016 values
- 417 in Swedish Krona (SEK) with the Harmonised Consumer Price Index. In 2017, 100 SEK \approx 10.5 Euros.
- 418 MS: Individuals with first registered MS diagnosis in 2009 (Y_0) in national in- and specialised out-
- 419 patient registers.

- Figure 2 Mean disposable income (DI) Y₋₇ to Y₊₄ among people diagnosed with multiple sclerosis
 (MS) in Y₀ (N=785) compared to references (N=7847)
- *Notes:* Mean annual DI inflated to 2016 values in Swedish Krona (SEK) with Harmonised Consumer
- 424 Price Index In 2017, 100 SEK ≈ 10.5 Euros. Year of diagnosis (2009=Y₀). MS (solid blue line):

425 Individuals with first registered MS diagnosis in 2009 (Y₀) in national in- and specialised out-patient

- 426 registers. References (dashed red line: matched on four variables $(1 \rightarrow 10)$ with no MS diagnosis
- 427 registered in years before 2010 in the national patient register.

BMJ Open

429 Acknowledgments: Not applicable.

Author Statement: CM, OM MW KK and PT participated in the design of the study. CM, OM and
MW performed data management, and CM, OM, MW and PT were involved in the data analyses. All
authors (CM, OM, MW, KA, KK, EF and PT) contributed to interpretation of results, participated in
the writing and reviewing of the drafts, and have approved the final version of the manuscript.

Competing interests statement: We have read and understood the BMJ policy on declaration of interests. All authors have completed the ICMJE uniform disclosure at www.icmje.org/coi disclosure.pdf and declare the following interests with respect to the research, authorship, and/or publication of this article: CM, PT, EF, and MW received financial support from Biogen for the submitted work. KA has received unrestricted research grants from Biogen. OM and KK had no competing interests to declare.

Funding: This work was supported by Biogen and the Swedish Research Council for Health, Working
Life and Welfare. The design of the study, data collection, analyses, interpretations of data, and
writing of manuscript was performed without involvement of the funding bodies, however, Biogen
was invited to comment on the manuscript.

Data Statement: No additional data available. The authors of this study are not permitted to make the micro-level data in this study publically available due to its sensitive nature. According to the Swedish Ethical Review Act, the Personal Data Act, and the Administrative Procedure Act, data can be made available after legal review for researchers who meet the criteria for access to this type of sensitive and confidential data. For questions about this, please contact Professor Kristina Alexanderson, responsible for the data set.

	DEFEDENCES
455	REFERENCES

- 456
 457 1. Fattore G, Lang M, Pugliatti M. The Treatment experience, burden, and unmet needs (TRIBUNE)
 458 study measuring the socioeconomic consequences of Multiple Sclerosis. *Multiple Sclerosis*459 *Journal* 2012;18(2 Suppl):5-6. doi: 10.1177/1352458512447262 [published Online First: 18
 460 Jun 2012]
 - 461 2. Ahlgren C, Oden A, Lycke J. High Nationwide Incidence of Multiple Sclerosis in Sweden. *PloS one*462 2014;9(9):e108599.
 - 463 3. Wiberg M, Friberg E, Stenbeck M, et al. Sources and level of income among individuals with
 464 multiple sclerosis compared to the general population: A nationwide population-based study.
 465 *Multiple Sclerosis Journal* 2015;21(13):1730–41. doi: 10.1177/1352458515570767
 - 466 4. Mills E, Mirza A, Mao-Draayer Y. Emerging approaches for validating and managing multiple 467 sclerosis relapse. *Frontiers in Neurology* 2017;8(116) doi: 0.3389/fneur.2017.00116
- 468 5. Brundin L, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in
 469 Europe: Results for Sweden. *Multiple Sclerosis Journal* 2017;23:179-91. doi:
 470 10.1177/1352458517708682
- 471 6. Krause I, Kern S, Horntrich A, et al. Employment status in multiple sclerosis: impact of disease472 specific and non-disease-specific factors. *Multiple Sclerosis Journal* 2013;19(13):1792–99. doi:
 473 10.1177/1352458513485655
 - 474 7. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in
 475 Europe. Journal of neurology, neurosurgery, and psychiatry 2006;77:918-26. doi:
 476 10.1136/jnnp.2006.090365
 - 8. Smith M, Arnett P. Factors related to employment status changes in individuals with multiple
 sclerosis. *Multiple Sclerosis Journal* 2015;11(5):602-09. doi: 10.1191/1352458505ms1204oa
- 479 9. Pearson J, Alla S, Clarke S, et al. Multiple Sclerosis impact on employment and income in New
 480 Zealand. Acta neurologica Scandinavica 2017;136(3):223–32. doi: 10.1111/ane.12714
- 481
 481
 481
 482
 482
 482
 483
 483
 483
 484
 484
 484
 485
 485
 486
 486
 487
 488
 488
 489
 480
 480
 481
 481
 482
 483
 484
 484
 484
 485
 486
 487
 488
 488
 489
 489
 480
 480
 481
 481
 482
 483
 484
 484
 484
 484
 485
 484
 485
 484
 486
 487
 487
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 - 484
 11. Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol

 485
 2014;122:343-69. doi: 10.1016/B978-0-444-52001-2.00014-5
 - 486
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
 487
- 37487disability in huttiple sclerosis: an annesic process. Brain 2003,120(Ft 4).77082.3848813. Gyllensten H, Wiberg M, Alexanderson K, et al. Costs of illness of multiple sclerosis in Sweden: a39489population-based register study of people of working age. The European journal of health40490economics : HEPAC : health economics in prevention and care 2017:1-12. doi:4149110.1007/s10198-017-0894-6
- 4249214. Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis43493in Europe. Multiple sclerosis 2017;23(8):1123-36. doi: 10.1177/1352458517694432
 - 494 15. Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis: a systematic review of the
 495 literature. *Pharmacoeconomics* 2010;28(5):363-79. doi: 10.2165/11532230-000000000496 00000
- 4749716. Wiberg M, Friberg E, Palmer E, et al. Sickness absence and subsequent disposable income: A48498population-based cohort study. Scandinavian journal of public health 2015;43(4):432-40. doi:4949910.1177/1403494815575341
- 5050017. Fritzell J, Nermo M, Lundberg O. The impact of income: assessing the relationship between51501income and health in Sweden. Scandinavian journal of public health 2004;32(1):6-16. doi:5250210.1080/14034950310003971
- 5350318. Solar O, Irwin A. A conceptual framework for action on the social determinants of health. Social54504Determinants of Health Discussion Paper 2 (Policy and Practice). Geneva: World Health55505Organization, 2010.

1		
2	506	19. Kavaliunas A, Danylaite Karrenbauer V, Gyllensten H, et al. Cognitive function is a major
3 4	500	determinant of income among multiple sclerosis patients in Sweden acting independently
5	508	from physical disability. <i>Multiple sclerosis</i> 2017:1352458517740212. doi:
6	509	10.1177/1352458517740212
7	510	20. Kavaliunas A, Wiberg M, Tinghög P, et al. Earnings and Financial Compensation from Social
8	511	Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients. PloS one
9	512	2015;10(12):e0145435. doi: 10.1371/journal.pone.0145435
10	513	21. Chruzander C, Tinghög P, Ytterberg C, et al. Longitudinal changes in sickness absence and
11	514	disability pension, and associations between disability pension and disease-specific and
12	515	contextual factors and functioning, in people with multiple sclerosis. Journal of the
13	516	neurological sciences 2016;367:319-25. doi: 10.1016/j.jns.2016.05.055
14	517	22. Landfeldt E, Castelo-Branco A, Svedbom A, et al. The long-term impact of early treatment of
15	518	multiple sclerosis on the risk of disability pension. J Neurol 2018 doi: 10.1007/s00415-018-
16	519	8764-4
17	520	23. Tinghög P, Hillert J, Kjeldgard L, et al. High prevalence of sickness absence and disability pension
18 10	521	among multiple sclerosis patients: a nationwide population-based study. Multiple sclerosis
19 20	522	2013;19(14):1923-30. doi: 10.1177/1352458513488234
20 21	523	24. Glad S, Nyland H, Aarseth J, et al. How long can you keep working with benign multiple sclerosis?
21	524	Journal of neurology, neurosurgery, and psychiatry 2011;82(1):78-82. doi:
23	525	10.1136/jnnp.2010.210732
24	526	25. Pfleger CC, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis (1): early
25	527	pension and temporary unemploymenta historical prospective cohort study. Multiple
26	528	sclerosis 2010;16(1):121-6. doi: 10.1177/1352458509352196
27	529	26. Jennum P, Wanscher B, Frederiksen J, et al. The socioeconomic consequences of multiple
28	530	sclerosis: a controlled national study. European neuropsychopharmacology : the journal of
29	531	the European College of Neuropsychopharmacology 2012;22(1):36-43. doi:
30	532	10.1016/j.euroneuro.2011.05.001
31	533	27. Marmot M. The Influence Of Income On Health: Views Of An Epidemiologist. Health Affairs
32	534	2002;21(2):31-46. doi: 10.1377/hlthaff.21.2.31
33	535	28. Galobardes B, Shaw M, Lawlor D, et al. Indicators of socioeconomic position (part 1). Journal of
34	536	epidemiology and community health 2006;60(1):7-12. doi: 10.1136/jech.2004.023531
35	537	29. Smith J. Healthy Bodies and Thick Wallets: The Dual Relation Between Health and Economic
36 27	538	Status. J Econ Perspect 1999;13(2):144-66.
37 38		
38 39	539	30. Salter A, Thomas N, Tyry T, et al. Employment and absenteeism in working-age persons with
40	540	multiple sclerosis. Journal of Medical Economics 2017;20(5):493-502. doi:
41	541	10.1080/13696998.2016.1277229
42	542	31. Galobardes B, Lynch J, Davey Smith G. Measuring socioeconomic position in health research.
43	543	British medical bulletin 2007;81-82:21-37. doi: 10.1093/bmb/ldm001
44	544	32. Thormann A, Sørensen P, Koch-Henriksen N, et al. Chronic comorbidity in multiple sclerosis is
45	545	associated with lower incomes and dissolved intimate relationships. European journal of
46	546	neurology 2017;24(6):825-34. doi: 10.1111/ene.13297
47	547	33. Hillert J, Stawiarz L. The Swedish MS registry - clinical support tool and scientific resource. Acta
48	548	neurologica Scandinavica 2015;132(199):11-9. doi: 10.1111/ane.12425
49	549	34. Lidwall U. Termination of sickness benefits or transition to disability pension after changes in
50	550	sickness insurance: a Swedish register study. <i>Disability and rehabilitation</i> 2013;35(2):118-24.
51	551	doi: 10.3109/09638288.2012.689920
52	552	35. Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the
53	553	clinical course of multiple sclerosis. <i>Multiple sclerosis</i> 2017;23(9):1233-40. doi:
54 55	554	10.1177/1352458516675039
55 56		
56 57		
57 58		
58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 26 of 30

BMJ Open

36. Statistika Centralbyrån. Bakgrundsfakta 2016:1 Longitudinell integrationsdatabas för

Sjukförsäkrings- och Arbetsmarknadsstudier (LISA) 1990-2013. Örebro: Statistics Sweden, Population and Welfare Department, 2016. 37. Statistika Centralbyrån. Konsumentprisindex (KPI) [Consumer price index]. Stockholm2016 http://www.scb.se/hitta-statistik/statistik-efter-amne/priser-och-[Available from: konsumtion/konsumentprisindex/konsumentprisindex-kpi/ accessed 14/08/17. 38. Lumley T, Diehr P, Emerson S, et al. The importance of the normality assumption in large public Health 2002;23:151-69. health data sets. Annu Rev Public doi: 10.1146/annurev.publheath.23.100901.140546 39. Liang K, Zeger S. Longitudinal Data Analysis Using Generalized Linear Models. Biometrika 1986;73(1):13-22. 40. Rahman S, Mittendorfer-Rutz E, Alexanderson K, et al. Disability pension due to common mental disorders and healthcare use before and after policy changes: A nationwide study. . Eur J Public Health 2017;27(1):90-96. 41. Hanley J, Negassa A, Edwardes M, et al. Statistical Analysis of Correlated Data Using Generalized Estimating Equations: An Orientation. American Journal of Epidemiology 2003;157(4):364-75. 42. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006;129(Pt 3):595-605. doi: 10.1093/brain/awh714 43. Mutual Information System on Social Protection (MISSOC). Your social security rights in Denmark: European Union,; [updated July 2013. Available from: ec.europa.eu/social/BlobServlet?docId=13746&langId=en. 44. Kavaliunas A, Karrenbauer VD, Gyllensten H, et al. Income and cognitive impairment among multiple sclerosis patients. Multiple Sclerosis Journal 2016;22:12-13. 45. Wiberg M, Friberg E, Palmer E, et al. Earnings among multiple sclerosis patients compared to individuals without multiple sclerosis, in total and for different educational levels and types of occupations - a longitudinal-based cohort study. ECTRIMS 2015 7-10 October; Barcelona, Spain. 46. Kavaliunas A, Karrenbauer VD, Tinghog P, et al. Cognitive function predicts work disability among multiple sclerosis patients. Multiple Sclerosis Journal 2017;23:479-80. 47. Landfeldt E, Castelo-Branco A, Svedbom A, et al. Sick leave and disability pension before and after diagnosis of multiple sclerosis. Multiple Sclerosis Journal 2016;22(14):1859-66. doi: 10.1177/1352458516667567 48. Gyllensten H, Wiberg M, Alexanderson K, et al. Comparing costs of illness of multiple sclerosis in three different years: A population-based study. Multiple Sclerosis Journal 2017; [Epub ahead of print]:1-9. doi: 10.1177/1352458517702549 [published Online First: March 1]

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml




Figure 1: Mean disposable income (DI) Y-7 to Y+4 among people diagnosed with multiple sclerosis (MS) in Y0. Notes: Mean annual DI with 95% confidence intervals illustrated. DI sums are inflated to 2016 values in Swedish Krona (SEK) with the Harmonised Consumer Price Index. In 2017, 100 SEK ≈10.5 Euros. MS: Individuals with first registered MS diagnosis in 2009 (Y0) in national in- and specialised out-patient registers.

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright.

117x83mm (300 x 300 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 28 of 30

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright.




Figure 2 Mean disposable income (DI) Y-7 to Y+4 among people diagnosed with multiple sclerosis (MS) in Y0 (N=785) compared to references (N=7847). Notes: Mean annual DI inflated to 2016 values in Swedish Krona (SEK) with Harmonised Consumer Price Index In 2017, 100 SEK ≈10.5 Euros. Year of diagnosis (2009=Y0). MS (solid blue line): Individuals with first registered MS diagnosis in 2009 (Y0) in national inand specialised out-patient registers. References (dashed red line: matched on four variables (1→10) with no MS diagnosis registered in years before 2010 in the national patient register.

119x82mm (300 x 300 DPI)

BMJ Open

Section/Topic	ltem #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1 & 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-10
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	7&9
		(d) If applicable, explain how loss to follow-up was addressed	7&9
		(e) Describe any sensitivity analyses	N/A

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright.

Page	30	of	30
------	----	----	----

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9 & 10
		(b) Indicate number of participants with missing data for each variable of interest	9, 11-12
		(c) Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	Report numbers of outcome events or summary measures over time	13-14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence	15-16
		interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	17
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from	17-21
		similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	19
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	22

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2017-020392 on 9 May 2018. Downloaded from http://bmjopen.bmj.com/ on January 6, 2024 by guest. Protected by copyright.